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MAPPING THE HUMAN VASCULATURE BY IN VIVO PHAGE DISPLAY 
 
Julianna Kim Bronk, B.S. 
Advisory Professor: George Calin, M.D., Ph.D. 
 
In vivo phage display screenings by intravenous injection of a random phage-displayed 
peptide library allow for the selection of peptides that localize to specific vascular beds. 
At the University of Texas MD Anderson Cancer Center, we have had the opportunity to 
perform phage display screenings in cancer patients in order to select for cancer specific 
targets directly in humans. These targets serve to define biochemical diversity of 
endothelial cell surfaces and can be validated and explored towards the design of 
vascular-targeted pharmacology. In the most recent patient screen, samples were 
recovered from hepatocellular carcinoma (HCC) as well as 26 additional tissues. High-
throughput sequencing and multidimensional bioinformatics analysis of recovered 
peptides led to the identification of extensive panels of motifs that are predicted to 
distinctly localize to tissue-specific vascular beds. Utilizing peptide affinity purification 
and phage based binding assays, we have shown that the HCC targeting peptide 
(SGVGAASL) identified from this patient screen, selectively binds to HCC in vitro as 
well as in vivo facilitated by a receptor mediated interaction with the giantin protein. 
FACS and protein fractionational experiments showed that the giantin polypeptide, 
normally considered an intracellular protein, is uniquely expressed on the surface of HCC 
cell lines as well as activated endothelial cells. shRNA mediated depletion of giantin 
expression lead to a loss of proliferation and adhesion in cancer cells. Finally, an 
extensive study of giantin expression in patient HCC tissue uncovered a unique 
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expression pattern on the surface of tumor-associated vasculature. Collectively, these data 
support a functional role for giantin on the surface of HCC tumor endothelium that could 
potentially be exploited for delivery of imaging and therapeutic agents. Ultimately, this 
work serves as the foundation of a high-throughput integrative platform for discovery and 
validation of tissue-specific motifs towards a comprehensive understanding of the 
vascular landscape in humans. 
 
  
viii 
 
TABLE OF CONTENTS 
 
DEDICATION……………………………………………………………………………iii 
ACKOWLEDGEMENTS………………………………………………………………...iv 
ABSTRACT……………………………………………………………………………...vi 
TABLE OF CONTENTS……………………………………………………….………viii 
LIST OF FIGURES……………………………………………………………………….x 
LIST OF TABLES………………………………………………………………….......xiii 
LIST OF ABBREVIATIONS………………………………………………………..…..xv 
CHAPTER 1: INTRODUCTION AND REVIEW OF THE LITERATURE .................... 1 
1.1  Overview of the vascular system ......................................................................... 1 
1.1.1  Endothelial cell heterogeneity....................................................................... 1 
1.1.2  Angiogenesis ................................................................................................. 2 
1.1.3 Anti-angiogenic therapy................................................................................ 3 
1.2  Bacteriophage ....................................................................................................... 4 
1.2.1  Phage display screening for molecular targets in cells ................................. 6 
1.2.2  In vivo phage display for proteomic profiling of blood vessels .................... 8 
1.2.3    Next-generation phage display ...................................................................... 11 
1.3  Analysis of high-throughput peptide screenings ................................................ 14 
1.4  Hepatocellular carcinoma ................................................................................... 17 
1.4.1  Current standard of care for localized HCC ............................................... 18 
1.4.2  Molecular targeted drugs for advanced HCC ............................................. 19 
CHAPTER 2: MATERIALS AND METHODS .............................................................. 21 
CHAPTER 3: RESULTS .................................................................................................. 50 
ix 
 
3.1  High-throughput combinatorial peptide screen in a cancer patient .................... 50 
3.2  Bioinformatic selection of tissue specific peptides ........................................... 62 
3.2.1 Generation of amino acid substitution matrices.......................................... 66 
3.2.2 Selection of tissue specific peptides by multidimensional analysis............ 69 
3.3  Peptide SGVGAASL mediated targeting of liver tumor cells .......................... 89 
3.4 Peptide SGVGAASL endogenous receptor purification .................................... 91 
3.5 Giantin expression in patient tissue .................................................................... 94 
3.5.1 Giantin expression in HCC patient samples ............................................... 97 
3.5.2 Giantin expression in a HCC tissue microarray .......................................... 99 
3.5.3 Giantin expression in normal patient tissue .............................................. 107 
3.5.4 Giantin expression in additional cancers .................................................. 107 
3.6  Giantin cell surface expression in HCC and endothelial cells ........................ 113 
3.7 Giantin function in HCC cells .......................................................................... 119 
CHAPTER 4: DISCUSSION .......................................................................................... 122 
CHAPTER 5: REFERENCES ........................................................................................ 134 
CHAPTER 6: VITA ........................................................................................................ 155 
  
x 
 
LIST OF FIGURES 
 
Fig. 1-1. General filamentous phage structure. ................................................................... 5 
Fig. 1-2. In vivo phage display. ........................................................................................ 10 
Fig. 1-3. Saturation plots of peptide diversity coverage after next-generation sequencing.
........................................................................................................................................... 13 
Fig. 1-4. Volume overlay of tyrosine and tryptophan generated by ROCS OpenEye 
Scientific Software. ........................................................................................................... 16 
Fig. 2-1. Schematic of phage display screen in a patient with HCC. ............................... 26 
Fig. 2-2. Bioinformatic workflow describing the selection of lead motifs from peptide 
sequences recovered from a phage display screen performed in a patient. ...................... 29 
Fig. 2-3. Bioinformatic workflow describing the selection of lead motifs from peptide 
sequences recovered from a phage display screen performed in a patient using 
multidimensional amino acid properties. .......................................................................... 31 
Fig. 2-4. Representation of oligos designed for construction of shRNA lentiviral vector 
targeting giantin ................................................................................................................ 45 
Fig. 3-1. Pathological analysis of a patient with HCC and RCC. ..................................... 51 
Fig. 3-2. Schematic of phage DNA amplification from human tissue and resulting 
amplicon layout. ................................................................................................................ 54 
Fig. 3-3. Schematic of raw data processing and database construction for sequencing data 
recovered from high-throughput phage display screens. .................................................. 56 
Fig. 3-4. Screenshot of user interface for online database of high-throughput phage 
display screening data. ...................................................................................................... 57 
xi 
 
Fig. 3-5. Output of peptide search function using newly designed online database for 
high-throughput phage display screening data. ................................................................ 58 
Fig. 3-6. Run ID search for online database of high-throughput phage display screening 
data. ................................................................................................................................... 59 
Fig. 3-7. Tissue search for online database of high-throughput phage display screening 
data. ................................................................................................................................... 60 
Fig. 3-8. Advanced Tissue search for online database of high-throughput phage display 
screening data.................................................................................................................... 61 
Fig. 3-9. Saturation curves for peptide sequences recovered from human liver and HCC 
autopsy samples following a high-throughput phage display screen................................ 63 
Fig. 3-10. BLOSUM62 analysis for amino acid substitution. .......................................... 67 
Fig. 3-11. ROCS scoring based amino acid substitution analysis. ................................... 71 
Fig. 3-12. SGVGAASL-peptide displaying phage binding and internalization in HCC 
cells. .................................................................................................................................. 90 
Fig. 3-13. SGVGAASL peptide homing to orthotopic HCC tumors in mice. .................. 92 
Fig. 3-14. Receptor purification for SGVGAASL peptide. .............................................. 93 
Fig. 3-15. SGVGAASL-peptide displaying phage binding to immunocaptured receptors.
........................................................................................................................................... 95 
Fig. 3-16. Giantin staining in HCC and normal liver tissue sections obtained from patient 
6......................................................................................................................................... 96 
Fig. 3-17. Giantin staining in archival tissue specimens from HCC patients. .................. 98 
Fig. 3-18. Giantin protein expression in HCC tissue specimens and adjacent normal liver 
tissue. .............................................................................................................................. 100 
xii 
 
Fig. 3-19. Giantin staining in human HCC cancer and benign liver tissue. ................... 101 
Fig. 3-20. Giantin staining in normal and diseased human liver tissue. ......................... 103 
Fig. 3-21. Giantin staining in HCC tissue by patient and tumor characteristics. ............ 104 
Fig. 3-22. Giantin staining in HCC vasculature. ............................................................. 106 
Fig. 3-23. Giantin staining in normal human tissue. ....................................................... 108 
Fig. 3-24. Giantin staining in human prostate cancer and normal prostate tissue. ......... 109 
Fig. 3-25. Giantin staining in human breast cancer and normal breast tissue. ............... 111 
Fig. 3-26. Giantin staining in human colon cancer and normal colon tissue. ................. 112 
Fig. 3-27. Giantin staining in human non-small cell lung cancer (NSCLC) cancer and 
normal lung tissue. .......................................................................................................... 114 
Fig. 3-28. Giantin staining in human ovarian cancer and normal ovarian tissue. ........... 115 
Fig. 3-29. SGVGAASL displaying phage binding to giantin purified from plasma 
membrane protein fraction of HCC cells. ....................................................................... 117 
Fig. 3-30. Cell surface expression of giantin on HCC cells and endothelial cells. ......... 118 
Fig. 3-31. Giantin knockdown in HEP3B cells............................................................... 120 
Fig. 3-32. Cell adhesion and proliferation kinetics following shRNA-mediated depletion 
of giantin in HEP3B cells. .............................................................................................. 121 
  
xiii 
 
LIST OF TABLES 
 
Table 3-1. Recovered peptide containing sequences from patient biopsy tissue samples in 
a high-throughput phage display screen. .......................................................................... 52 
Table 3-2. Recovered peptide containing sequences from patient autopsy tissue samples 
in a high-throughput phage display screen ....................................................................... 53 
Table 3-3. Overview of recovered peptide containing sequences from high-throughput 
phage display screen in a cancer patient. .......................................................................... 64 
Table 3-4. Tissue-specific peptides selected from liver tumor tissue. .............................. 65 
Table 3-5. Amino acid substitution matrices. ................................................................... 68 
Table 3-6. Grouping of amino acids based on 2-dimensional characteristics including 
size, charge, aromaticity, and hydrophobilicity. ............................................................... 70 
Table 3-7. Summary of motif selection analysis performed using the BLOSUM62 amino 
acid substation matrix and simple score ranking for all patient tissues recovered. .......... 73 
Table 3-8. Summary of motif selection analysis performed using the BLOSUM62 amino 
acid substation matrix and combination score ranking for all patient tissues recovered. . 74 
Table 3-9. Summary of motif selection analysis performed using the 2-dimensional 
properties amino acid substation matrix and simple score ranking for all patient tissues 
recovered. .......................................................................................................................... 75 
Table 3-10. Summary of motif selection analysis performed using the 2-dimensional 
properties amino acid substation matrix and combination score ranking for all patient 
tissues recovered. .............................................................................................................. 76 
xiv 
 
Table 3-11. Summary of motif selection analysis performed using ROCS derived amino 
acid substation matrix and simple score ranking for all patient tissues recovered. .......... 77 
Table 3-12. Summary of motif selection analysis performed using ROCS derived amino 
acid substation matrix and combination score ranking for all patient tissues recovered. . 78 
Table 3-13. Summary of motif selection analysis performed using ChemGPS-4D amino 
acid substation matrix and simple score ranking for all patient tissues recovered. .......... 79 
Table 3-14. Summary of motif selection analysis performed using ChemGPS-4D amino 
acid substation matrix and combination score ranking for all patient tissues recovered. . 80 
Table 3-15. Summary of motif selection analysis performed using ChemGPS-9D amino 
acid substation matrix and simple score ranking for all patient tissues recovered. .......... 81 
Table 3-16. Summary of motif selection analysis performed using ChemGPS-9D amino 
acid substation matrix and combination score ranking for all patient tissues recovered. . 82 
Table 3-17. Peptides clustering to top 100 motifs in all 10 analyses. ............................... 83 
Table 3-18. Peptides clustering to top 100 motifs in all analyses using simple score motif 
ranking. ............................................................................................................................. 84 
Table 3-19. Peptides clustering to top 100 motifs in all analyses using combination score 
motif ranking. .................................................................................................................... 85 
Table 3-20. Top motifs from liver tumor analysis cross-referenced with biologically 
relevant peptides. .............................................................................................................. 86 
Table 3-21. Peptide SGVGAASL clustering to top 100 motifs in liver tumor tissue. ..... 88 
  
xv 
 
LIST OF ABBREVIATIONS 
 
BRASIL Biopanning and Rapid Analysis of Selective Interacting Ligands 
BSA   Bovine serum albumin 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
ChemGPS Chemical Global Positioning System 
Cy3  Cyanine dye-3 
Da  Dalton 
DAB  3,3'-diaminobenzidine 
DAPI   4’,6-diamidino-2-phenylindole 
DMEM  Dulbecco's Modified Eagle’s Medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleotide triphosphates  
E. coli   Escherichia coli 
EGM  Endothelial cell growth media   
EDTA  Ethylenediaminetetraacetic acid 
ER   Endoplasmic reticulum 
FACS   Fluorescence-activated cell sorting 
FBS   Fetal bovine serum 
FDA   Food and Drug Administration  
FITC   Fluorescein 
GRP78 Glucose regulated protein-78 
HCC   Hepatocellular carcinoma  
HDMEC Human dermal microvascular endothelial cells 
xvi 
 
HNPCC  Hereditary Non-Polyposis Colon Cancer 
HPLC   High performance liquid chromatography 
HRP   Horseradish peroxidase 
HSP-90 Heat-shock protein-90  
IHC   Immunohistochemistry 
IR  Infrared 
kan   Kanamycin 
LB   Luria-Bertani  
LC-MS/MS  Liquid chromatography-tandem mass spectrometry 
mRNA  Messenger ribonucleic acid 
NSCLC Non-small cell lung cancer 
NP-40  Tergitol, nonyl phenoxypolyethoxylethanol 
nt  Nucleotide  
PAH  Pulmonary artery hypertension  
PBS  Phosphate buffered saline 
PCA   Principal component analysis 
PCR   Polymerase chain reaction 
PFA   Paraformaldehyde 
Phage   Bacteriophage 
RCC  Renal cell carcinoma 
RNA  Ribonucleic acid 
ROCS  Rapid Overlay of Chemical Structures 
rpm  Revolutions per minute 
RT   Room temperature 
S1  Simple score 
xvii 
 
S2  Combined Score 
S. aureus  Staphylococcus aureus 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
shRNA Short hairpin ribonucleic acid 
strep  Streptomycin 
TBS   Tris buffered saline 
tet   Tetracycline 
TMA  Tissue microarray 
TMB  3,3’,5,5’-tetramethylbenzidine 
Tris  Tris(hydroxymethyl)aminomethane 
TU   Transducing units 
UV-Vis  Ultraviolet–visible 
VEGF  Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
1 
 
CHAPTER 1: INTRODUCTION AND REVIEW OF THE LITERATURE 
 
1.1  Overview of the vascular system 
During vertebrate development, the cardiovascular system is the first organ 
system to be formed and reach a functional state. The vascular system makes up an 
intricate network that connects each of the organ systems of the body with the vital 
purposes of transporting oxygen and nutrients to tissues and exporting waste from tissues 
[1]. Vessels are composed of an inner lining or endothelium made up of endothelial cells 
that arrange into an epithelial layer that surrounds the internal lumen of the vessel. In 
small vessels, the endothelium consists of vascular smooth cells and pericytes whereas in 
large arteries and veins, smooth muscle cells, connective tissue, collagen and elastic 
fibers form the support structure [1-3]. This structure allows vessels to dynamically adapt 
to changing demands for nutrients and oxygen throughout the body. In extreme cases of 
chronic changes, the remodeling of vascular beds may be required to restore homeostasis.  
 
1.1.1  Endothelial cell heterogeneity 
Phenotypic heterogeneity across the so called “vascular tree” is the core property 
of the vascular system. Variations in structural as well as molecular properties in the 
endothelium play a critical role in many physiological functions including vasomotor 
tone, leukocyte trafficking, hemostasis, permeability, angiogenesis, and immunity [4]. 
Phenotypic endothelial cell heterogeneity provides the endothelium with the ability to 
meet the varied needs of tissues throughout the body. For example, under conditions of 
acute or chronic inflammation, endothelial cells are able to induce permeability by 
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regulation of cell junctions as well as allow for site specific receptor mediated 
transcytosis [4, 5]. Traditionally, identification of various endothelial cell phenotypes has 
been performed using, immunohistochemistry, in situ hybridization, intravital 
microscopy, and proteomic techniques such as antibody and phage screenings [5-7]. 
 
1.1.2  Angiogenesis  
Angiogenesis, the formation of new vessels from existing vasculature, occurs 
during embryonic development to establish the foundation of the vascular system for 
growing and developing organs [8]. In adults, angiogenesis is involved in physiological 
repair processes such as wound healing and occurs in a highly ordered, tightly regulated 
fashion [9]. Under normal conditions, angiogenesis induces quiescent endothelial cells to 
extend the vascular network only to the extent that meets the demands of growing tissue. 
This process requires a coordinated signaling network of various mediators including 
soluble growth factors (vascular endothelial growth factor (VEGF), fibroblast growth 
factor, platelet-derived growth factor, and transforming growth factor-β) and membrane-
bound molecules enabling cell-cell interactions (αvβ3-integrin, VE-cadherin, and eph-
B4/ephrin-B2) [8]. 
 In order to satisfy the metabolic demands for proliferation and survival, tumor 
cells, host-derived cells that have lost the ability to regulate growth, retain characteristics 
that are similar to non-transformed cells including the need for a supply of oxygen, 
delivery of nutrients, and removal of waste. Initially, tumors can grow around established 
vasculature in order to meet their metabolic needs. Tumor-induced angiogenesis occurs 
when the existing vasculature is inadequate to sustain tumor survival and it must establish 
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its own blood supply through neovascularization [10, 11]. Exploiting angiogenesis to 
promote disease has several key advantages. First, it allows for the critical transport of 
oxygen, nutrients, and waste to and from the disease site. Second, newly developed blood 
vessels share host immunity, therefore, allowing the tumor to evade immunologic attack. 
Finally, conditions in the tumor create a proliferative phenotype in endothelial cells that 
are normally quiescent allowing for continuous growth of vessels to support the tumor [8, 
12, 13]. Although the formation of tumor-associated vasculature is made possible by 
commandeering host angiogenic mechanisms, the vessels themselves are structurally 
abnormal. These abnormalities include distended and convoluted vessels, a lack of 
functional pericytes, and general “leakiness” due to fenestrae or holes in the incomplete 
basement membrane [8]. Interestingly, tumor vasculature may contain both endothelial 
cells and tumor cells (“mosaic” tumor vessels) [14]. 
 
1.1.3 Anti-angiogenic therapy 
Physiological and pathological inhibitors of angiogenesis have been explored in 
the context of cancer therapeutics. The strategy behind anti-angiogenic therapy is to 
develop an agent that will inhibit blood vessel growth, thus, suppressing the ability of the 
tumor to proliferate and survive. Many angiogenesis inhibitors are already undergoing 
clinical trials [8]. For example, in 2004, bevacizumab (Avastin), a monoclonal antibody 
targeting VEGF-A developed by Genentech/Roche, was the first targeted anti-
angiogenesis cancer therapy to be approved by the Food and Drug Administration (FDA) 
and has since become the most widely prescribed anti-angiogenic therapy in various 
types of cancer [15]. However, many targeted anti-angiogenic therapies are limited by 
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drug resistance, side effects, and toxicity including a risk of hypertension, gastrointestinal 
disorders, and hemorrhaging [16]. In particular, recent studies have shown evidence of 
increased aggression in tumor recurrence following the withdrawal of anti-angiogenic 
therapy likely due to the selective pressures promoting tumor invasion and metastasis 
such as a hypoxic microenvironment and survival of resistant cell subpopulations [17]. 
Interestingly, an endogenous angiogenesis inhibitor, endostatin, a 20 kDa protein derived 
from the proteolytic cleavage of collagen XVIII, has been shown to inhibit endothelial 
cell proliferation, angiogenesis, and tumor growth in mice and no resistance has been 
observed in humans [18, 19]. Unfortunately, during clinical trials, no significant 
improvements in tumor response or progression were observed in patients treated with 
endostatin alone. Subsequent studies have shown that endostatin may be beneficial in 
combination with other therapies [20]. Additional strategies to develop anti-angiogenic 
agents as a form of cancer vaccine to prevent tumor development at early stages are also 
underway [8]. Despite the current shortcomings in anti-angiogenic therapy, there remain 
many avenues for improvement and optimization towards the improvement of clinical 
cancer care. 
 
1.2  Bacteriophage 
Phage display was first described by George Smith as a technique to identify 
antibody binding sites. In this seminal study, filamentous bacteriophage (phage), a single 
stranded DNA virus that infect gram-negative bacteria, were genetically engineered to 
express or “display” a short protein sequence taken from the EcoRI endonuclease gene on 
the outer phage capsid protein III (pIII) (Fig. 1-1) [21]. These modified “fusion phage”  
 
 Fig. 1-1. General filamentous phage structure.
protein structure and arrangement
proteins, molecular weight, size and copy number per virion. 
from Løset GÅ, Roos N, Bogen B, Sandlie I. Expanding the Versatility of Phage Display 
II: Improved Affinity Selectio
Filamentous Phage. PLoS ONE. 2011. 6(2): e17433. Copyright: © 2011 Løset et al. This 
is an open-access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestric
provided the original author and source are credited. 
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 a) Schematic of bacteriophage coat 
. b) Individual representation of bacteriophage coat 
Reprinted with permission
n of Folded Domains on Protein VII and IX of the 
ted use, distribution, and reproduction in any medium, 
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particles retained their ability to infect and replicate in bacteria, and after panning for 
affinity to an antibody against EcoRI, they were found to be enriched over normal wild 
type phage. This technique has since been widely explored and expanded for various 
applications aimed at discovering and understanding important protein-protein 
interactions. Phage-displayed peptide libraries have been constructed with a diversity of 
greater than 109 different clones per library displaying random peptides on the pIII capsid 
that vary in length and contain frequent cysteine residues thereby creating conformational 
“loops” in the sequence displayed [22]. These combinatorial libraries have proven to be 
tremendously advantageous for the development of screening methodologies used to 
isolate peptide ligands. 
 
1.2.1  Phage display screening for molecular targets in cells 
Phage display has been used as a methodology to perform systemic profiling of 
protein expression for clinically relevant markers in various settings including circulating 
antibodies, recombinant proteins and isolated protein extracts, and cell lines [23-30]. 
Phage libraries were used to investigate tumor specific antibodies found in the serum of 
prostate cancer patients, leading to the identification of a cyclic peptide that selectively 
bound to tumor-associated antibodies over control antibodies from blood donors [23]. 
This study was extended to show that the identified peptide mimicked a region of the 
tumor antigen, glucose regulated protein-78 (GRP78), known to be overexpressed in 
cancer. Further identification and examination of GRP78 binding motifs in preclinical 
prostate cancer models demonstrated that GRP78 is a strong candidate for targeted  
therapy in metastatic prostate cancer [25]. In a similar study in ovarian cancer, antibody 
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fingerprinting by phage display combinatorial selection was performed to identify tumor-
related antibodies present in ascities fluid in patients with advanced disease [24]. A 
consensus motif was isolated from this screen and was found to mimic heat-shock 
protein-90 (HSP-90). In a large panel of ovarian cancer patients, HSP-90 expression was 
found to be elevated; however, humoral response was restricted to patients with stage IV 
disease. 
Likewise, phage display technology has also been directly applied towards 
elucidating the details of protein-protein interactions with the goal to identify potential 
small ligand inhibitors of cancer and other diseases. In a study involving DNA repair, a 
screen performed on cell nuclear extract prepared from irradiated cells uncovered a 
ligand binding to and inactivating DNA-dependent protein kinase involved in DNA 
double-strand break repair. This inactivating ligand was also found to sensitize BRCA-
deficient cancer cells to genotoxic therapy [26]. This approach takes advantage of 
synthetic lethality where inhibition of a DNA-repair pathway target as well as the 
presence of a mutation due to selective pressures during tumor evolution may sensitize 
tumor cells while having no effect on healthy cells. Similarly, in a study to uncover 
binding mechanisms of Staphylococcus aureus (S. aureus) mediated through microbial 
surface components recognizing adhesive matrix molecules, a phage panning directly on 
recombinant SdrC, natively expressed in S. aureus, uncovered a novel interaction 
mediating bacterial colonization in host tissues [27]. Knowledge of this interaction could 
potentially lead to the design and development of antimicrobial therapies. 
In 2001, Giordano et al. developed a methodology for probing the cell surface in 
vitro using combinatorial phage-displayed libraries by organic phase separation [28]. The 
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initial characterization of this protocol was implemented to identify peptide ligands 
binding to the VEGF receptor (VEGFR) expressed on the surface of endothelial cells and 
has since been extended to numerous cell lines. For example, Kolonin et al., performed a 
phage-displayed random peptide library screen in a panel of 60 cell lines derived from 
human tumors (NCI-60) [29]. Just as gene arrays have been used to identify similarities 
and differences between tumor types, the diversity of peptides recovered allowed for 
profiling of cell surface markers present in each cell line. By classifying cell lines by 
recovered tri-peptide motifs, Kolonin et al. were able to identify domains of human 
proteins that serve as ligands to receptors in tumor cells and classify the cell lines in the 
NCI-60 panel by expression profiles of their corresponding tumor receptors. Several 
peptide motifs mimicking native ligands of the epidermal growth factor receptor were 
validated for binding specificity and targeting ability in these studies [29, 30]. 
 
1.2.2  In vivo phage display for proteomic profiling of blood vessels 
In vitro methods for protein profiling do not take into account the physiological 
context of protein-protein interactions. In particular, interactions occurring in specific 
vascular beds that are accessible by therapeutic agents traveling in the bloodstream 
represent ideal candidates for targeted delivery applications [5, 31]. Furthermore, 
angiogenic vessels have been known to express receptors or other molecules that are not 
present in normal blood vessels [6]. Attempts to isolate endothelial cells ex vivo by 
freshly harvesting them from animals are problematic because once removed from their 
native environment, these cells may undergo phenotypic drift introducing artifacts into 
subsequent findings [32, 33]. For example, in a study by Durr et al., over 40% of proteins 
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expressed on the plasma membrane of rat lung microvascular endothelial cells were not 
detected in vitro after cells were harvested and cultured [33]. Study of vascular 
proteomics in vivo has been explored by several groups beginning with the identification 
of peptides homing to normal and tumor blood vessels (Fig. 1-2a) [34, 35]. Since this 
initial work, phage-displayed peptide libraries have been used to screen for molecular 
targets using various preclinical models including disease of the lymph node, brain, 
prostate, breast, and fat tissue [36-40].  
Accessible proteins in the vasculature of diseased tissues have the potential to 
serve as excellent targets for therapy strategies (Fig 1-2b). This specificity not only 
allows for increased therapeutic effects but also may minimize damage to healthy cells. 
Furthermore, previous drug candidates of limited effectiveness may gain efficacy when 
directly targeted to a disease site. The use of in vivo models for phage display is 
immensely beneficial because it grants the ability to uncover targets under native 
conditions. Furthermore, several of these screens have indicated that the selected tissue 
specific peptides often mimic biological ligands that can be important for disease 
establishment and progression. In these cases, the peptides themselves may exhibit 
therapeutic properties by interfering with interactions required for disease persistence 
[41, 42].  
Despite the utility of preclinical models, experiments performed in artificial 
settings must be carefully validated before being extrapolated to human applications. 
Direct selection of phage libraries in a patient was first reported by Arap et al. in 2002 
[31]. In this large-scale screening, 47,160 tri-peptide motifs were identified to localize to 
normal or tumor-associated vasculature and the tissue distribution of these peptides was  
 Fig. 1-2. In vivo phage display.
receptors expressed on the surface of tissue endothelium. b) These peptide ligands can be 
used for directing therapy to specific tissues and organs. Reprinted with permission from 
Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for 
therapy. Curr Opin Chem Biol. 2001 Jun;5(3):308
Science Ltd. 
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 a) Peptide ligands displayed on phage can home to 
-13. Copyright: © 2001 Elsevier 
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determined to be nonrandom. This work led to the generation of a targeted drug for 
patients with metastatic prostate cancer. A peptide found to mimic interleukin 11 and 
bind to the interleukin 11 receptor alpha which is upregulated on the surface of bone-
marrow metastasis was conjugated to a pro-apoptotic moiety (D[KLAKLAK]2). This 
formulation, called bone-marrow targeting peptide 11, has since been shown to be 
therapeutically active in several types of cancer including prostate cancer metastasis to 
bone, osteosarcoma, and osteosarcoma metastasis to lung [43, 44] as well as non-small 
cell lung cancer (NSCLC) and leukemia (data in preparation). Subsequent screenings in 
patients have been performed with the overarching goal of mapping human vasculature 
heterogeneity towards the development of molecularly targeted drugs and imaging 
agents. 
 
1.2.3    Next-generation phage display 
Recent advances in sequencing capabilities have revolutionized the field of 
genomics; however, it is widely accepted that DNA sequence alone is not sufficient to 
fully describe how proteins function and interact in their environment. The combination 
of high-throughput sequencing and combinatorial phage display has been applied towards 
building a more complete understanding of protein function and protein-protein 
interactions. In either an in vitro or in vivo phage display screen, the two rate-limiting 
steps include quantifying phage homing (traditionally performed by allowing particles to 
infect bacteria and confer resistance, selecting for infected bacteria by plating on agar 
containing antibiotics, and counting colonies the following day) as well as identification 
of the amino acid sequence of the peptide displayed on each phage by DNA sequencing 
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of individual bacterial colonies. To address these limitations, Dias-Neto et al. [45] 
eliminated the reliance on host bacteria and utilized real-time PCR for rapid phage 
quantification and high-throughput sequencing for large-scale analysis of phage display 
screening data. By implementing these improvements, they were able to perform phage 
display screenings 1,000 x faster and 250 x cheaper while recovering over 100 x more 
sequences. For example, high-throughput sequencing enabled recovery of over 1 million 
peptide inserts per run whereas traditional Sanger sequencing was limited to the number 
of bacterial colonies manually tested. Furthermore, the analyzed sequence dataset 
included over 90% of the phage diversity present in each targeted tissue suggesting that 
the diversity in these tissues was covered (Fig 1-3). By leveraging this exponential 
increase in recovered data from a single screen, a panel of novel protein-protein 
interactions were identified in a patient screen and four were further validated and 
characterized in the context of normal and disease tissues [46]. 
Following the development of next-generation technologies for large-scale phage 
screenings, several other groups have utilized this technology for high-throughput phage 
display applications. Di Niro et al. have developed and characterized a cDNA phage 
library displaying open reading frames of the human genome [47]. They identified 
several known as well as novel protein-protein interactions involving the 
transglutaminase 2 enzyme interaction network by large scale recovery of phage 
sequences. Likewise, Fowler et al. have developed a high-throughput approach for 
investigating sequence variation in the context of ligand binding towards optimized drug 
development [48]. By performing multiple rounds of selection coupled with deep- 
  
 Fig. 1-3. Saturation plots of peptide diversity coverage after next
sequencing. The number of distinct pep
muscle (c), skin (d) or the non
number of peptide sequences evaluated for each tissue. Adapted from Dias
Nunes DN, Giordano RJ, Sun J, Botz GH, e
Integrating and Comparing Available Molecular Tools to Enable Cost
Throughput Analysis. PLoS ONE. 2011. 4(12): e8338. Copyright: © 2009 Dias
al. This is an open-access article distributed under th
Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are credited. 
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sequencing of recovered phage, they were able to identify regions of the human WW 
domain that were essential for binding to its peptide ligand.  
 
1.3  Analysis of high-throughput peptide screenings 
Diverse phage libraries yield vast sequence datasets and impose great demands 
for efficient evaluation of experimental results. Contemporary amino acid–alignment and 
assessment programs for high-throughput sequencing data analysis are needed to quickly 
and reliably interpret consensus motifs from the phage sequences recovered in screenings 
to facilitate the discovery of protein partners and reveal new tissue specific molecular 
targets [49]. 
Protein sequence alignment can be performed at several different levels including 
bioinformatic similarities, structural and pharmacophoric properties, and molecular 
characteristics. In the early 1990s, the BLOSUM62 matrix was considered one of the 
most efficient amino acid substitution matrices for sequence alignment applications. By 
examining sequence similarity in related proteins, the probability of amino acid 
substitution could be estimated and amino acids could be optimally grouped [50]. 
 Drug screening tools can also be adapted for protein similarity identification 
applications. Shape comparison can be more accurate than sequence-based alignments 
such as BLOSUM62 when applied towards predicting molecular interactions [51, 52]. 
For example, the molecular alignment program ROCS (Rapid Overlay of Chemical 
Structures), was developed by OpenEye Scientific Software (Sante Fe, New Mexico) as a 
virtual screening tool with the capability to overlay representative volumes as a measure 
of similarity between molecular shapes with mismatched volumes representing 
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dissimilarity (Fig. 1-4). Furthermore, pharmacophoric characteristics are also taken into 
account in the scoring algorithm. These three dimensional alignments can be valuable in 
several applications including predicting protein structures and revealing binding 
elements between different molecules [53].  
An additional drug screening program designed by Oprea et al. in 2001 is the 
chemical global positioning system (ChemGPS) or “drugspace” map developed by 
applying geographical-like characteristics such as longitude and latitude as well as the 
concept of structural objects such as landmarks and cities to a chemical or drug space. 
These characteristics when applied towards molecules include aspects such as size, 
hydrophobicity, polarizability, electrostatic charge, structural flexibility or rigidity, and 
dipole-dipole attraction [54]. Coordinates on the map are represented by t-scores 
measured from a total of 423 “core” structures (representative drugs) and “satellite” 
structures (molecules that contain characteristics way outside the drug space). Principal 
component analysis (PCA) was used to predict scores for many other chemicals and 
amino acids, building a comprehensive map of drug interrelationships [54]. The 
ChemGPS tool is especially attractive when applied towards comparing different 
molecules by simultaneously taking into account various dimensions and characteristics.  
For applications in high-throughput phage display data, ROCS as well as 
ChemGPS programs can be adapted to serve as valuable tools for identifying consensus 
motifs in tissues of interest by not only taking into account amino acid sequence, but also 
the overall shape and predicted biological activity of the peptide.  
 
  
 Fig. 1-4. Volume overlay of tyrosine and t
Scientific Software. ROCS 3.2.0.4: OpenEye Scientific Software, Santa Fe, NM. 
http://www.eyesopen.com.  
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1.4  Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the 5th most common type of cancer found in 
adults and the 3rd most common cause of cancer death [55]. There are approximately 
630,000 new cases per year with about 80% of cases occurring in developing countries 
including sub-Saharan Africa, East and Southeast Asia, and Melanesia [56]. Risk factors 
for HCC include alcohol intake, hepatitis B virus, hepatitis C virus, exposure to toxins, 
and obesity [55, 57]; however, chronic liver disease is the main etiological factor 
associated with all cases of HCC [56]. A main characteristic of cirrhotic liver is a 
decrease in hepatic vasculature which subsequently leads to a hypoxic environment in the 
injured tissue. In response, cells upregulate hypoxia inducible factor-1α which goes on to 
stimulate the production of additional angiogenic signaling molecules including VEGF 
and several matrix metalloproteinases in an attempt to restore vascularization [58, 59]. 
Misregulation of these angiogenic and inflammatory signals can lead to damage of the 
surrounding liver tissue, inhibition of tissue regeneration, and eventually the development 
of HCC [55, 60].  
Screening for HCC is performed by measuring serum levels of alfafetoprotein or 
routine monitoring of the liver by ultrasound imaging [55]. Unfortunately, the disease is 
usually detected when the tumor has progressed to an advanced and incurable stage. 
Metastasis accounts for almost 90% of cancer associated mortality and is the least 
understood aspect of cancer pathogenesis [61]. 
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1.4.1  Current standard of care for localized HCC 
Treatment decisions for HCC are heavily based on tumor size and staging. In the 
past, the only curative treatment for HCC was partial hepatectomy or liver transplantation 
if the tumor was small (10-30% or cases) or local ablative therapy for patients who were 
not surgical candidates [56]. Surgical resection of HCC tumors carries an increased 
mortality rate when compared to resection for benign disease or liver metastasis from a 
primary tumor not originating in the liver most likely due to the increased burden of 
disease associated with cirrhosis [62]. Therefore, the ideal candidates for HCC resection 
are those with early stage local disease lacking major vascular invasion and having well 
managed cirrhosis.  
Liver transplantation is an ideal therapy choice because this treatment modality 
can mediate both the HCC as well as underlying liver damage. For HCC patients that 
meet the criteria for transplantation (small solitary tumor without vascular invasion or 
metastasis) the reoccurrence rate is around 5-15% with 5 year survival of over 70% [55, 
63]. In fact, liver transplantation offers better disease-free and overall survival compared 
with resection in patients that meet the criteria (66% 5-year survival for transplantation 
compared to 46% 5-year survival for resections) [64]. Despite the improved outcomes 
associated with transplantations, a major limitation is the availability of organs. Patients 
on the waiting list for a liver transplant may have their cancer progress causing them to 
be removed from the list. 
An alternative to surgical interventions for treatment of HCC is local ablative 
therapy. These treatments induce tumor cell death by modifying cell temperatures using 
lasers, microwaves, radiofrequency, or cryoablation [55]. As these technologies have 
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become more widely accepted, an increased amount of data has been collected as to the 
outcomes and benefits. For small HCC tumors that have not metastasized, 5-year survival 
rates of 40-70% have been reported for ablative therapy [55, 65]. Many patients will 
undergo neo-adjuvant ablative therapy while on the waiting list for a transplant. 
 
1.4.2  Molecular targeted drugs for advanced HCC 
Unfortunately, many patients with HCC are not eligible for localized treatments 
due to extra-hepatic metastasis and macroscopic vascular invasion. HCC is a chemo-
resistant tumor, therefore, systemic chemotherapy is not an effective treatment [66-68]; 
however, recent studies have shown that combination chemotherapy may enable the 
tumor to become resectable [67]. Currently, the molecularly targeted drug, sorafenib, 
which interferes with the mitogen-activated protein kinase signaling pathway has been 
the only drug that increases the overall survival of patients with advanced HCC [56, 69].  
Sorafenib counteracts angiogenic signaling critical for HCC tumor establishment, growth 
and progression and has been successful in treating advanced HCC systemically. In a 
clinical trial, the median overall survival for patients with advanced HCC treated with 
sorafenib was 10.7 months compared to 7.9 months in a placebo group [69].  
Due to sorafenib’s success as the first drug found to be effective in patients with 
advanced HCC, many subsequent studies of molecularly targeted agents have been 
performed with the hopes of improved patient outcomes. Despite a wide range of studies, 
no therapeutic target has of yet shown efficacy in Phase III trials [55]. Given the 
frequency and mortality associated with HCC and its metastasis, there is a clear need for 
identification of improved therapeutic targets. HCC is commonly referred to as a 
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hypervascular tumor [55, 70] and the recent advancement of anti-angiogenic molecular 
therapies suggests that this may represent an ideal direction for improvements in the 
treatment of advanced HCC. 
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CHAPTER 2: MATERIALS AND METHODS 
 
Reagents. The following primary antibodies were used: rabbit polyclonal anti-
bacteriophage (Sigma), HRP-conjugated monoclonal anti-bacteriophage antibody (GE 
Healthcare Life Sciences), rabbit polyclonal anti-giantin antibody (Abcam), rat 
polyclonal anti-Orc2 antibody (Millipore), rabbit polyclonal anti-MEK1/2 antibody 
(CellSignaling), and mouse monoclonal anti-58K antibody (Abcam). The following 
secondary antibodies were used: HRP-conjugated anti-rabbit IgG, Cy3- conjugated anti-
rabbit IgG (both obtained from Jackson ImmunoResearch Laboratories), biotinylated 
anti-rabbit IgG (Vector Laboratories), FITC-conjugated anti-rabbit (Life Technologies), 
FITC-conjugated anti-mouse (Life Technologies), and FITC-conjugated anti-rat (Life 
Technologies). All synthetic peptides were commercially synthesized by PolyPeptide 
Laboratories. 
 
Cell culture. HEP3B, HEPG2, and SNU449 HCC cells (ATCC) were maintained in 
Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS), 
100 units/mL penicillin, 100 ug/mL streptomycin, and 2 mM L-glutamine and cultured at 
37°C in a humidified 5% CO2 incubator. Human Dermal Microvascular Endothelial Cells 
(HDMECs) were maintained in EGM™-2 MV media containing 5% FBS and growth 
supplements (Lonza Group, Ltd.) and cultured at 37°C in a humidified 5% CO2 
incubator. 293FT cells (Life Technologies) were maintained in DMEM (high glucose), 
10% FBS, 0.1 mM non-Essential Amino Acids, 6 mM L-glutamine, 1 mM sodium 
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pyruvate, and 500 ug/ml Geneticin® (Life Technologies) and cultured at 37°C in a 
humidified 5% CO2 incubator. 
 
Preparation of phage libraries. Both CX7C and CX8C phage display random peptide 
libraries were used for screening in patient 6. Primary unamplified phage libraries were 
produced in order to decrease the likelihood of having an over-representation of certain 
phage clones. Previously, the preparation of highly diverse phage libraries (109 peptide 
permutations) has been described in [71]. Briefly, preparation is based on cloning DNA 
fragments encoding for short peptides into the fUSE5 phage genome vector. The 
fragments are cloned into the pIII capsid coat protein gene so that peptides will be 
displayed on the surface of the phage and be able to interact with potential targets. First, 
the fUSE5 plasmid is grown in Escherichia coli (E. coli) MC1061 F’-minus bacteria 
maintained in LB- tet/strep medium [71]. This vector was initially designed to be non-
infective due to the insertion of a disrupting “stuffer” sequence in the gene III reading 
frame [71]. When the stuffer sequence is replaced by an in frame sequence, infectivity is 
restored. fUSE5 vector was digested with the restriction enzyme SfiI which removed the 
stuffer sequence and resulted in overhangs that are incompatible with one another. This 
allows for unidirectional cloning of a DNA insert that is digested with the Bgl1 restriction 
enzyme [21, 71]. Synthetic inserts were purchased as single strand oligonucleotides with 
the sequence: 
5’ CACTCGGCCGACGGGGCT (NNK)X GGGGCCGCTGGGGCCGAA 3’ 
Where N indicates random nucleotides (nt), K indicates either a G or T in order to 
prevent the presence of stop codons in the sequence, and X represents the number of 
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amino acids desired in the peptide library. After ligation of the insert into digested 
fUSE5, the vector was electroporated into MC1061 (at least 100 electroporations/library) 
and amplified by shaking at 225 rpm at 37°C overnight.  
 Phage particles were amplified by infecting K91/ kanamycin (kan) bacteria grown 
to log phase for 20 min at room temperature (RT). The infected bacteria were then 
cultured in media containing 0.2 ug/mL tetracyclin (tet) in order to induce the phage tet 
resistance gene. Following induction, bacteria were cultured overnight at 37°C in LB 
media containing 20 ug/mL of tet and 100 ug/mL of kan. Cultures were next centrifuged 
at 5,000 x g for 10 min and phage were precipitated with 16.5% polyethylene glycol and 
3.3 M sodium chloride. After resuspending precipitated phage in phosphate buffered 
saline (PBS), phage were quantified by bacterial infectivity assays on kan/tet selective 
agar plates containing both 100 ug/mL kan and 40 ug/mL tet. Phage were diluted in PBS 
and infected with log phage K91 E. coli in kan media for 20 min at RT. The bacteria were 
plated in triplicate onto the kan/tet plates and incubated overnight at 37°C. Colonies were 
counted to determine the transducing units (TU) per uL based on the phage starting 
dilution [72]. The resulting library should contain 1011 – 1012 TUs of phage. Likewise, 
about 100-1000 copies of each peptide can be expected to be represented in the library 
[72]. Next, endotoxins were removed from the library as described in [73] because it 
would be administered intravenously to a patient. Sterilized phage libraries were stored at 
4°C in saline until administration.  
 
Real time PCR for phage quantification (qPhage). Phage were quantified using the 
qPhage protocol described in [45]. Briefly, phage samples were diluted 1:20. 5 uL of the 
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dilute phage sample was mixed with 1 x Fast SYBR Green PCR Mastermix (Applied 
Biosystems) and 3.75 pmole of each of the primers: 
forward:5’- TGAGGTGGTATCGGCAATGA- 3’  
reverse: 5’- GGATGCTGTATTTAGGCCGTTT-3’ 
for a final reaction volume of 15 uL. These primers amplify a region on the tet resistance 
gene located on the fUSE5 plasmid. The amplification program consisted of 50°C for 2 
min, 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min. A standard 
curve was generated from serial 1:10 dilutions of a known concentration of phage (106 to 
102 plasmids). The amount of phage in each reaction was determined by comparing the 
amplification threshold for each sample to the standard curve. All amplifications were 
run in triplicate.  
 
Phage display screen in a patient. The study design was reviewed and approved by the 
Institutional Review Board of the University of Texas M. D. Anderson Cancer Center 
(MDACC # ID99-417) and follows the established ethics framework and guidelines [74, 
75]. A 53 year-old male patient had been newly diagnosed with HCC and was on his way 
to be treated at the University of Texas MD Anderson Cancer Center. During the trip, the 
patient claimed to have chest pain and lost consciousness. At the emergency room, he 
was found to be unresponsive and in cardiopulmonary arrest. The patient sustained 
hypoxic brain injury and was made do not resuscitate. Following approval, a starting dose 
of 1013 TUs of CX7C and CX8C phage library was intravenously injected into the patient. 
Needle tissue biopsies were collected 15-30 min following infusion according to 
Biosafety Level 1 protocols and kept on ice. The patient was then weaned from life-
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support systems and autopsy samples were collected 72 hr following phage library 
injection after the patient was pronounced dead (Fig. 2-1). Tissue samples were handled 
taking standard precautions associated with blood and bodily fluids. 
 
Sequencing of individual phage. In order to confirm the correct peptide insert located 
on phage after production or amplification, phage colonies were transferred into 30 uL of 
10% glycerol for storage at -20°C. For a finalized phage preparation, phage were diluted 
1:1000 in PBS. The PCR reaction contained 2 uL of the bacteria/glycerol mixture or 
diluted phage, 8 pmol of forward and reverse primers specific for fUSE5: 
forward: 5’- AGCAAGCTGATAAACCGATACAATT - 3’  
reverse: 5’- CCCTCATAGTTAGCGTAACGATCT -3’ 
0.5 uL of 10 mM dNTPs,  2 uL of 25 mM MgCl2, 4 uL of 5 x GoTaq Polymerase buffer 
(Promega), 2 units of GoTaq DNA polymerase (Promega), 0.4 uL of dimethyl sulfoxide 
(DMSO), and water to a final volume of 20 uL. PCR reactions were carried out under the 
following conditions: 94°C for 3 min, 35 cycles of 94°C for 10 sec, 60°C for 30 sec and 
72°C for 1 min, followed by 72°C for 3 min. The DNA was sequenced by the Sequencing 
Core Facility at the University of Texas M.D. Anderson Cancer Center. 
 
High-throughput phage sequencing. High-throughput phage sequencing protocols were 
adapted from [45]. Tissues obtained from in vivo phage display screens (25 mg/sample) 
were ground using the Precellys®24 tissue homogenizer (Bertin Technologies). Tissue 
digestion and DNA extraction was performed using a DNeasy Blood and Tissue Kit 
(QIAGEN) and the final elution was done with 200 uL of sterile water. Amplification of  
  
 
Fig. 2-1. Schematic of phage display screen in a patient with HCC.
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the region of phage DNA containing the peptide insert was performed using primers 
specific to the fUSE5 vector:  
forward: 5’ TAG- CGCAATTCCTTTAGTTGTTCC 3’  
reverse: 5’ TGAATTTTCTGTATGAGGTTTTGC 3’   
We designed a system of tagging peptides extracted from specific tissues by performing 
the initial DNA amplification with a unique three to six base pair sequence at the 5’ end 
of the forward primer. Six base pair tag sequences had at least 2 base pair difference and 
no more than 2 guanines or cytosines. The tagging system allows for the pooling of PCR 
products from each tissue for sequencing in a single run and requires post sequencing 
processing to determine the tissue of origin for each sequence. Phage DNA was amplified 
using the Kapa HiFi DNA Polymerase Kit (Kapa Biosystems) for high fidelity PCR 
amplification products. The PCR reaction contained 1.5 uL of 10 mM dNTPs, 5 uL of 5 x 
GC Buffer, 2 uL of 25 mM MgCl2, 0.64 uL of KAPA HiFi DNA Polymerase, 16.5 pmols 
of each primer, 5 uL of DNA, and water to a final volume of 25 uL. The reaction mix was 
placed in a thermocycler and heated to 95°C for 2 min, with 35 cycles of 98°C for 20 sec, 
60°C for 15 sec, and 68°C for 10 sec. After amplification, each sample was separated on 
a 4% agarose gel where the desired product was between 140-150 nt in size. If 
contamination at other sizes were present, the 140-150 nt bands were excised from the 
gel and purified using a QIAquick Gel Extraction Kit (QIAGEN). Following purification, 
samples were combined and purified using a DNA Clean & Concentrator™-5 Kit (Zymo 
Research) and eluted 2 x with 25 uL of water. DNA was quantified and sent to the MD 
Anderson Sequencing Core for high-throughput sequencing. 
 
28 
 
Raw data processing and peptide extraction. Given the great number of sequences 
generated using large-scale sequencing (on the order of 106 – 108 sequences per run), an 
online sequence submission and analysis system for processing raw data was developed 
using PERL scripts and a MySQL relational database management system. Peptide insert 
sequences were extracted and sorted based on their tissue of origin and a newly 
developed data mining tool was designed to allow for users to directly search for peptides 
of interest. A tagging system was used to label peptides extracted from specific tissues by 
performing the initial DNA amplification with a unique short sequence at the 5’ end of 
the forward primer. Peptide insert sequences were extracted based on the identification of 
both the flanking regions of the insert and the identification of this unique tag designating 
the sample of origin. Sequence quality analysis was also performed to ensure the 
reliability of each read. Exact base pair identification of the clone structure, identification 
tag, amplification primers, and the flanking region of the insert was ideal; however, 
minor sequencing discrepancies were allowed for in the clone structure, primer, tag, and 
flanking sequence when extracting peptide sequences in order to utilize the full spectrum 
of data. Additionally, saturation data analysis was performed to determine the coverage 
of phage diversity for each tissue. The number of distinct peptides observed in a tissue or 
sample of choice was compared to the total number of sequences evaluated for that tissue 
or sample. This system allowed for a single multi-functional program for easy lab 
member access and analysis of newly acquired data. 
 
Bioinformatic analysis for peptide selection. A bioinformatic workflow was developed 
to identify and prioritize lead peptide candidates for further validation (Fig. 2-2). Peptide  
 
 Fig. 2-2. Bioinformatic workflow describing the selection of lead motifs from peptide 
sequences recovered from a phage 
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display screen performed in a patient.
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sequences were gathered into groups, and assigned a unique label based on source tissue 
and sample. Biologically similar groups were further aggregated into pools.  Correlative, 
non-correlative, and anti-correlative relationships between the pools were defined such 
that tissue-specific features could be identified through statistical testing. Significance 
scores were computed for sequences from each tissue, versus tissues belonging to 
negatively correlated pools. Those with Fisher Exact Test p-values < 0.05 (one-sided) 
were selected for further analysis. Peptide sequences selected for analysis were assigned 
to clusters based on common tri-peptide segments. The clusters were then refined by 
extending tri-peptide segments into patterns of 4, 5, and 6 amino acids, effectively 
creating a tree of sub-clusters exhibiting incrementally greater sequence similarity. 
Patterns that fail to yield Fisher test p-values < 0.05 versus sequences from negatively 
correlated pools were next excluded. The remaining clusters were then prioritized 
according to the total number of matching sequences and processed using ClustalW 
alignment software (EMBL-EBI). The resulting sequence alignments were finally 
manually reviewed for internal consistency. Sequences containing multiple tryptophans 
and the sequences RGD or NGR were excluded from the analysis. 
 
Multidimensional analysis for peptide selection. In a secondary bioinformatics 
analysis, alternative properties of peptide inserts were taken into account to identify 
enriched motifs in specific tissues (Fig. 2-3). Five different amino acid substitution 
matrices were utilized to account for different amino acid properties including shape and 
pharmacophoric activity [50, 54, 76]. Next, all unique forward and reverse motifs were 
generated from the peptides found in all tissues. The size of motifs ranged from 1-8  
  
 
 
Fig. 2-3. Bioinformatic workflow describing the selection of lead motifs from peptide 
sequences recovered from a phage display screen performed in a patient using 
multidimensional amino acid properties.
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residues. Concurrently, a scaled frequency value was calculated for every unique peptide 
in the data set where: 
	
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A normalization value (n) of 20,000 was used for the patient 6 data set because that was 
the median number of peptides found in each tissue. A sum of the scaled frequencies was 
calculated for all peptides found in each motif in each tissue. A ranking score was 
calculated using two methodologies based on Bayesian smoothing [77]. First, a simple 
score (S1) was calculated to select for motifs containing peptides that were found at a 
high frequency in a tissue. Second, a combined score (S2) was calculated to select for 
motifs containing many unique peptides all matching to a specific motif in the same 
tissue.  
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< %>?@A3 for all patterns, and  
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A small increment was added to give higher priority to longer motifs over shorter motifs 
containing the same peptides and the top motifs were selected for each analysis. 
 
Principal component analysis. For several amino acid substitution strategies, a 
similarity matrix was calculated based on given parameters of amino acid similarity and a 
principal component analysis (PCA) was used to reduce the dimensionality and explain 
the variance of the data. Analysis was performed by eigenvalue decomposition of the 
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similarity matrix. Variable diagnostics, R2 and Q2, were calculated to determine estimates 
of goodness of fit and prediction respectively. By graphing each attribute by each 
component, a useful visualization of the data set was obtained and the 20 natural amino 
acids were clustered into groups based on multidimensional similarity. 
 
Internalization Assay. To examine phage internalization in cell lines, 104 cells/well 
were plated on 16-chambered culture slides (BD Falcon) and allowed to attach and grow 
overnight at 37°C. Following incubation, cells were blocked with 1% bovine serum 
albumin (BSA) in media for 1 hr at 37°C then incubated with 108 - 109 TUs of 
SGVGAASL displaying phage or insertless phage (as a negative control) for 24 hr at 
37°C in media containing 2% FBS. Non-internalized phage were removed by washing 
each well 5 x with 10% BSA in PBS, 5 x with glycine buffer (50 mM glycine, 150 mM 
NaCl, pH 2.8) shaking at RT for 3 min each wash, and, finally, 3 x in PBS. Cells were 
next fixed with 4% paraformaldehyde (PFA) in PBS for 5 min at RT followed by 
washing 3 x with PBS. Next, cells were permeabilized by incubation with 0.2% Triton X-
100 in PBS at RT for 5 min, rinsed 5 x with PBS, and blocked with 1% BSA in PBS at 
RT for 2 hr. The cells were then incubated with rabbit anti-bacteriophage antibody 
diluted 1:500 in 1% BSA in PBS for 2 hr at RT followed by 5 washes with 1% BSA in 
PBS for 2 min each. Secondary antibody (Cy3-conjugated anti-Rabbit IgG) was added to 
the wells and allowed to incubate for 1 hr at RT. Wells were again washed 5 x with 1% 
BSA in PBS for 1 min each. For fluorescent microscopy, cells were fixed in 4% PFA in 
PBS for 5 min at RT, washed 2 x with PBS and mounted using VECTASHIELD with 
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DAPI (Vector Laboratories). Images were acquired with an Olympus fluorescence 
microscope. 
 
Phage binding assay (BRASIL). Cell surface binding in vitro was performed using the 
BRASIL method [28]. Briefly, cells were grown on 75 cm2 plates to 80% confluence and 
washed 3 x with PBS. Cells were released from the plate by the addition of 4 mL of cold 
PBS and 5 mM ethylenediaminetetraacetic acid (EDTA) to the plate. Cells were collected 
into a 15 mL falcon tube and the final volume was increased to 15 mL with 1% BSA in 
DMEM. Next, cells were counted and pelleted by centrifugation at 500 x g for 5 min. 
Cells were resuspended, aliquoted in 5 x 105 cells increments and incubated on ice. A 
phage solution was prepared in 1% BSA in DMEM at 1x 108 phage/tube. SGVGAASL 
displaying phage or insertless phage (as a negative control) were used. The cell/phage 
mixture was incubated on ice for 2 hr, then transferred carefully over 200 uL of non-
miscible organic lower phase (dibutyl phthalate: cyclohexane, vol/vol, 9:1; ρ = 1.03 
g/ml), and centrifuged at 10,000 x g for 10 min at RT. During centrifugation, phage 
particles bound to the surface of the cells were pulled down through the oil into the pellet 
while unbound phage remained at the top of the oil. The tube was then snap frozen at -
80°C for 15 min, and the bottom of the tube containing the pellet was removed and added 
to 200 uL of log phase K91 bacteria for infection at RT for 30 min. Dilutions of infected 
bacteria were plated on LB kan/tet plates and allowed to grow at 37°C overnight. The 
next day, colonies were counted.  
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Immunocapture phage binding assays. In a 96-well plate, 2 ug/mL of anti-giantin 
antibody was plated per well and incubated overnight at 4°C. The next morning, unbound 
antibody in solution was removed and remaining antibody was blocked with 200 uL/well 
of 1% BSA in PBS at 4°C for 8 hr. Protein extract was centrifuged for 10 min at 4°C at 
10,000 x g. After blocking, 20 µg of protein extract was added to each well and allowed 
to incubate overnight at 4°C. The next day, the plate was washed 3 x with 0.05% Tween 
in PBS and blocked for 1 hr in 200 uL 1% BSA at 4°C. Next, 1010 TUs of phage/well 
were diluted in PBS (50 uL) and incubated for 2 hr shaking at RT. Solution in wells was 
discarded and washed 12 x with 200 uL/well PBS. Quantification of phage was 
performed in two ways. First, bound phage were eluted with 25 uL glycine buffer (50 
mM glycine, 150 mM NaCl, pH 2.8) for 5 min at RT and particles were quantified using 
qPhage. Second, a phage enzyme-linked immunosorbent assay (ELISA) was performed 
by incubating wells with HRP-conjugated anti-phage antibody (diluted 1:4,000 in 50 
uL/well) and washing wells 3 x with 0.05% Tween 20 and 0.01% Triton X-100 in PBS.  
HRP detection was performed by incubation with TMB substrate (70 uL/well) for 30 min 
followed by quenching of the reaction with 70 uL of 1M, 2 N H2SO4 and quantification 
using an ultraviolet–visible (UV-Vis) spectrometer (450 nm). 
 
Cultured cell protein extraction. Cells were plated on a 20 cm2 dish and allowed to 
grow to at least 60% confluence at 37°C in a humidified 5% CO2 incubator. The 
following steps were carried out on ice. Cell media was aspirated and cells were washed 
2 x with chilled PBS. 500 uL/dish of chilled NP-40 lysis buffer (150mM NaCl, 50mM 
Tris pH 8.0, 1% NP-40, 0.5% BSA, 1 tablet of Phosphatase Inhibitors Cocktail (Sigma), 
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1 tablet of Protease Inhibitor Cocktail (Sigma)) was added dropwise to the surface area of 
the plate. Next, dish sides were tapped gently then the dish was scraped using a sterile 
cell scraper to remove attached cells. The buffer and cells were transferred to a 1.5 mL 
Eppendorf tube and left 2 hr spinning at 4°C for lysis to occur. Following lysis, tubes 
were centrifuged at 15,000 rpm for 10 min at 4°C to pellet debris. Supernatant was 
recovered and stored at -80°C. 
 
Tissue protein extraction. Human HCC tissue and normal human liver tissue samples 
were obtained from ILS Bio. Tissue was ground in PBS and centrifuged at 4,000 g for 5 
min at 4°C. The supernatant was stored at -80°C and the pellet was resuspended 
overnight in 5 mL extraction buffer (1 mM phenylmethanesulfonylfluoride, 1 mM CaCl2, 
1 mM MgCl2, 50 mM octylglucoside, 0.01% Triton X-100 in TBS). The next day, tubes 
were centrifuged at 4,000 g for 5 min at 4°C and the pellet was resuspended in 1 mL 
extraction buffer and transferred to 2 mL tissue homogenizing tubes containing 2.8 mm 
stainless steel beads (Precellys hard tissue grinding MK28 beads, Bertin Technologies). 
Tissue was homogenized in a Precellys®24 tissue homogenizer and incubated at 4°C 
overnight for foam to go down. The next day, tissue was centrifuged at 10,000 rpm for 15 
min at 4°C. The supernatant was filtered using Stericup® Steritop® Vacuum Filtration 
Filters (0.45 um, Millipore) and protein concentration was measured. Protein was divided 
into aliquots and stored at -80°C. 
 
Plasma membrane protein fractionation. Cells were grown in complete media 
(DMEM 10% FBS) to at least 60% confluence on three 20 cm2 dishes. The following 
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steps were all performed on ice. Cell media was aspirated and cells were washed 2 x with 
chilled PBS. Next, 5mL of chilled PBS was added to the plate and adherent cells were 
scraped off of the plate using a sterile cell scraper. Cells in PBS were transferred to a 
15mL tube and protein extraction was performed using Qproteome Plasma Membrane 
Protein Kit (QIAGEN). The plasma membrane fraction was resuspended in 0.5% Triton 
X-100 in PBS to a final volume of 400 uL. The protein concentration was measured and 
plasma membrane proteins were divided into aliquots and stored at -80°C. 
 
Peptide affinity chromatography. Receptors specific to selected peptides were isolated 
using peptide affinity chromatography. First, peptides were conjugated to long arm amine 
terminated magnetic beads (Bioclone Inc.). 1 mL of beads in a 15 mL falcon tube were 
used per conjugation. Tubes were placed on magnetic stands to separate beads from 
buffer. Buffer was removed and beads were resuspended in 3mL of coupling buffer (10 
mM KH2PO4, 150 mM NaCl, pH 5.5). Beads and coupling buffer were allowed to stand 
at RT on the magnetic stand. Buffer was removed and beads were resuspended in 3 mL 
coupling buffer 2 additional times. After the final wash, beads were resuspended in 1 mL 
of coupling buffer and combined with 1 mL of a 5 mg/mL solution of peptide diluted in 
water. Peptide and beads were mixed thoroughly and 400 uL of 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, 4 mM) was made fresh and added. The 
solution was left rotating for 24 hr at RT. The next day, beads were washed 3 x with 5 
mL of water and an additional 3 x with wash/storage buffer (10 mM Tris, 500 mM NaCl, 
0.1% BSA, 1 mM EDTA, 0.1% sodium azide, pH 7.5). Protein extract (10 mg/tube) was 
added to peptide conjugated beads and incubated overnight spinning at 4°C (final volume 
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adjusted to 5 mL with extraction buffer). The next day, beads were washed 10 x for 3 min 
spinning with extraction buffer (the supernatant from first removal was saved and stored 
at -20°C). Protein bound to peptide conjugated beads were eluted 3 x in 500 uL 0.1 M 
glycine pH 2.2. Peptide conjugated beads were stored at 4°C in 10 mL PBS. 
 
2-dimensional protein separation. Protein isolated by peptide chromatography was 
quantified and interfering contaminants including detergents, salts, lipids, phenolics and 
nucleic acids were removed using a 2-D clean-up kit from GE Healthcare Life Sciences 
(2 µg of protein per cleanup). Following cleanup, pellets containing protein were 
resuspended in 125 uL/ sample of rehydration buffer (8 M urea, 2% CHAPS, 40 mM 
dithiothreitol, 0.5%  IPG buffer (GE Healthcare Life Sciences), 0.002% bromophenol 
blue). 2-D gel electrophoresis was performed using the ZOOM® IPGRunner™ System 
(Life Technologies). The final gel was stained using SYPRO® Ruby Protein Gel Stain 
(Life Technologies) and imaged using a 300 nm ultraviolet transilluminator. 
 
Mass spectrometry analysis. Fractionated proteins isloated by peptide affinity were 
separated by 2D SDS-PAGE and compared to control fractions. Unique bands were 
excised from the SDS gels and digested with trypsin.  After extraction of the peptides, 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was performed 
by the Proteomics Core Facility at The University of Texas MD Anderson Cancer Center 
and a list of peptide masses was generated. Sequence databases were cross-referenced 
with the list of peptide masses to identify with high confidence proteins existing in the 
original sample.  
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Protein quantification. Protein quantification was performed using a standard 
bicinchoninic acid assay. Briefly, protein was diluted 1:10 and 1:100 in PBS. Serial 
dilutions of a BSA standard were prepared. In a 96-well plate, 5 uL of each dilution was 
added to a 1:50 dilution of working solution (ThermoScientific) and incubated at 37°C 
for 30 min. UV-Vis was used to measure the wavelength at 562 nm. A standard curve 
was generated from the BSA dilutions and sample concentration was extrapolated. 
 
Western blot for protein expression. Purified protein was centrifuged at 4°C for 10 min 
at 10,000 rpm to remove cellular debris. Each sample was mixed with 1x NuPAGE® 
LDS Sample Buffer (Life Technologies) and incubated at 100°C for 5 min to denature. 
Samples were then loaded onto a NuPAGE® Novex® 4-12% Bis-Tris Protein Gel (Life 
Technologies) and run at 100 V for 7 min then 200 V for 40 min or until the loading 
buffer ran to the bottom. Protein transfer from the gel to a nitrocellulose membrane was 
performed using an iBlot® Gel Transfer Device (Life Technologies). The membrane was 
rinsed with PBS then blocked in blocking solution (5% milk, 0.1% Tween-20 in TBS) for 
30 min rocking at RT. Primary antibody was added to 5 mL of fresh blocking solution 
and diluted as per manufacturer’s recommendation. Membranes were allowed to incubate 
with primary antibody overnight at 4°C rocking. The next day, membranes were washed 
3 x in washing solution (0.1% Tween-20 in TBS) for 5 min each with agitation. They 
were then incubated for 1 hr rocking with HRP-conjugated secondary antibody at a 
1:4,000 dilution in blocking solution. Again, the membrane was washed 3 x in washing 
solution for 5 min on a shaker. Chemiluminescent detection was performed with 
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Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life 
Sciences).  
 
Peptide dye conjugation. SGVGAASL peptide conjucation to IRDye 800 CW was 
performed as per manufacturer’s instructions (LI-COR). In brief, equimolar amounts of 
dye in DMSO were incubated with peptide in PBS at 4°C overnight on a rotating 
platform under dark conditions. Dye conjugated peptides were purified by reverse-phase 
high performance liquid chromatography (HPLC) using a Zorbax C18 HPLC column 
(Agilent Technologies) in a gradient mixture of acetonitrile and water buffered with 
triethylammonium acetate (50 mM, pH 6.0). Purified conjugate was dried using a vaccum 
evaportator, quantified by UV-Vis (774 nm), and stored in the dark at -20°C until use. 
 
Orthotopic mouse model of HCC. Orthotopic tumors were grown in the liver of male 
BALB/c nude mice (4–5 weeks in age) using the HEP3B liver cancer cell line (2 x 106 
cells in 50 uL) as described in [78]. When tumors reached the appropriate size (about 4 
weeks following impantation), SGVGAASL peptide labeled with IRDye 800CW infrared 
dye (excitation at 780 nm and emission at 794 nm) were injected intravenously at a dose 
of 10 µg, 15 µg, 30 µg, or 50 µg into tumor-bearing mice. Images were acquired by a 
Pearl Impulse Small Animal Imaging System (LI-COR) after 72 hr of circulation. All 
animal procedures were reviewed and approved by the University of Texas MD 
Anderson Cancer Center Institutional Animal Care and Use Committee. 
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Immunohistochemistry of patient samples. A commercially available antibody was 
used to examine the expression of giantin in patient samples by immunohistochemistry 
(IHC). Sections from snap-frozen or formalin-fixed, paraffin-embedded human tissue 
specimens were immunostained. Slides were deparaffinized, rehydrated, and washed. 
Antigen retrieval was performed and endogenous HRP activity was eliminated with 
hydrogen peroxide. Slides were treated overnight at 4°C with primary antibody diluted 
1:100. Slides were then washed and incubated with HRP-conjugated anti-rabbit IgG 
secondary antibody and developed with DAB substrate. Finally, slides were counter-
stained with hematoxylin, dehydrated, and mounted on coverslips for light field 
microscopy. 
 
Tissue microarray. Antibody titration experiments were conducted with an anti-giantin 
antibody to establish antibody concentrations that would minimize background and 
maximize signal detection. Serial dilutions were performed at 20 ug/ml, 10 ug/ml, 5 
ug/ml, and 2.5 ug/ml on formalin-fixed, paraffin-embedded normal human tissues as well 
as a sample of patient 6 HCC. Signal was detected using a biotinylated anti-rabbit 
secondary and a VectaStain ABCAP kit with a Vector® Red Alkaline Phosphatase 
Substrate Kit, which produced a fuchsia-colored deposit. Tissues were also stained with a 
positive control antibody (CD31/vimentin) to ensure that the tissue antigens were 
preserved and accessible for immunohistochemical analysis. Only tissues that exhibited 
positive staining for CD31/vimentin were included in the remainder of the study. As a 
negative control, the entire IHC procedure was performed on adjacent sections in the 
absence of primary antibody. Staining intensity was recorded on a 0-4 scale (0=negative, 
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1=minimal, 2=faint, 3=moderate, 4=strong). A series of human tissues including a 142 
sample tissue microarray (TMA) obtained from BioChain (Z7020057) comprised of 
normal liver (N=4), hepatocellular carcinoma (N=117), cholangiocarcinoma (N=14), 
colon adenocarcinoma metastasis (N=1), and inflammatory liver tissue (N=6) as well as 
18 single sections (N=3 each of 6 cancer types) were examined using the protocol 
described above. Slides were stained at an optimized antibody concentration of 5 ug/ml 
and imaged with a DVC 1310C digital camera coupled to a Nikon microscope. In 
addition to staining intensity, localization of the staining pattern was determined 
(cytoplasmic, membranous, nuclear, extracellular, and perinuclear expression). 
 
Flow cytometry- live cells. Cells were harvested (300,000 cells/sample) and washed 
with 1% BSA by centrifugation at 5,000 rpm for 2 min at 4°C. Next, cells were blocked 
in a solution containing 1% BSA and 1% IgG from human serum (Sigma) for 15 min on 
ice. Blocked cells were next incubated with primary antibody diluted as per 
manufacturer’s instructions in 1% BSA and allowed to incubate for 30 min on ice. Cells 
were washed 3 x with 1% BSA (250 uL/sample) by centrifugation at 5,000 rpm for 2 min 
at 4°C. FITC-conjugated secondary antibody was diluted in 1% BSA (0.5 ug/sample, 
final volume of 100 uL/sample) and allowed to incubate on ice for 20 min. Samples were 
again washed 3 x with 1% BSA (250 uL/sample) by centrifugation at 5,000 rpm for 2 
min at 4°C. Finally, cells were fixed by incubating with 4% fresh PFA for 5 min and 
washed 3 x with 1% BSA (250 uL/sample) by centrifugation at 5,000 rpm for 2 min at 
RT. Samples were resuspended in 300 uL 1% BSA for FACS analysis.  
 
43 
 
Flow cytometry- permeabilized cells. Cells were harvested (> 500,000 cells/sample) 
and washed with 1% BSA by centrifugation at 5,000 rpm for 2 min at RT. Next, cells 
were fixed for 10 min in 4% fresh PFA and washed 3 x in 1% BSA by centrifugation at 
5,000 rpm for 2 min at RT. Cells were then blocked in a solution containing 1% BSA and 
1% IgG from human serum (Sigma) for 15 min and permeabilized by incubation with 
Permeabilization solution (BD Cytofix/Cytoperm™ Fixation/Permeabilization Kit, 10 x 
concentrate FBS and saponin, diluted 1:10 in distilled water prior to use) for 15 min at 
RT. Cells were next incubated with primary antibody diluted as per manufacturer’s 
instructions in Permeabilization solution and allowed to incubate for 30 min at RT. Cells 
were washed 3 x with 1% BSA (250 uL/sample) by centrifugation at 5,000 rpm for 2 min 
at RT. FITC-conjugated secondary was diluted in Permeabilization solution (0.5 
ug/sample, final volume of 100 uL/sample) and allowed to incubate at RT for 20 min. 
Samples were again washed 3 x with Permeabilization solution (250 uL/sample) by 
centrifugation at 5,000 rpm for 2 min at RT. Finally, cells were fixed a second time by 
incubating with 4% fresh PFA for 5 min and washed 3 x with 1% BSA (250 uL/sample) 
by centrifugation at 5,000 rpm for 2 min at RT. Samples were resuspended in 300 uL 1% 
BSA for FACS analysis.  
 
Activated endothelial cells. HDMEC cells were cultured in EGM™-2 MV media 
containing 5% FBS and growth supplements (Lonza Group, Ltd.). Cells were starved in 
EGM™-2 MV Basal media not containing growth factors or FBS for 24 hr then activated 
with 50 ng/ml recombinant human VEGF (Millipore Corporation) for 4 hr. 
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shRNA cloning. The pLKO.1 puro vector was used to produce short hairpin RNA 
(shRNA) specific to giantin. The vector contains an ampicillin resistance gene (AmpR) 
for selection in bacterial cells and a puromycin resistance gene (PuroR) for selection in 
mammalian cells. The human U6 promoter which drives RNA Polymerase III for 
transcription of the shRNA transcript is located upstream of a 1.9 kb stuffer that is 
released by digestion with enzymes EcoRI and AgeI. We designed oligos specific to 
mRNA coding for giantin. General criteria that were met included identifying sequences 
about 21 nt in length, avoiding regions close to start and termination codons, avoiding 
regions with repeats and low complex sequences, and avoiding off-target effects on 
alternative genes. The double stranded oligo structure is shown in Fig. 2-4a where red x’s 
indicate sense sequences and green x’s indicate antisense sequences. A sequence 
compatible with the AgeI digestion site (CCGG) was added to the 5’ overhang of the 
forward oligo. On the 3’ end, a sequence (TTAA) was added to allow for compatible 
ligation with an EcoRI digested overhang. In the center of both the forward and reverse 
oligos is a spacer sequence (5’-CTCGAG-3’) that allows for the formation of a loop 
when annealed (Fig. 2-4a).  The oligos specific for the giantin mRNA transcript are 
shown in Fig. 2-4b and each sequence was previously validated by Sigma Aldrich. Oligos 
were dissolved in TE buffer (10 mM, pH 8.0) to a final concentration of 100 uM.  An 
annealing mixture was prepared by combining 10 uL of 10 x annealing buffer (1 M 
NaCL, 10 mM EDTA pH 8.0, 100 mM Tris-HCl pH 8.0), 2 uL of the forward and reverse 
oligos (2 uM each per annealing reaction), and 86 uL of water to a final volume of 100 
uL. Annealing was performed in a thermocycler by heating to 93°C for 3 min, 80°C for  
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Fig. 2-4. Representation of oligos designed for construction of shRNA lentiviral 
vector targeting giantin. a) Complimentary oligo schematic is shown. Red indicates 
sense sequence; green indicates antisense sequence. b) Representation of three oligo pairs 
designed to target the giantin (GOLGB1) mRNA transcript.   
Construct shRNA [GOLGB1.1]  
  
GOLGB1.1(+) [58 nt] :  
5’ CCGGgcttctgcttaatctgagaatCTCGAGattctcagattaagcagaagcTTTTTG 3’  
GOLGB1.1(-) [58 nt] :  
5’ AATTCAAAAAgcttctgcttaatctgagaatCTCGAGattctcagattaagcagaagc 3’ 
  
Construct shRNA [GOLGB1.2]  
  
GOLGB1.2(+) [58 nt] :  
5’ CCGGgcagacaatctcaagttgaaaCTCGAGtttcaacttgagattgtctgcTTTTTG 3’  
GOLGB1.2(-) [58 nt] :  
5’ AATTCAAAAAgcagacaatctcaagttgaaaCTCGAGtttcaacttgagattgtctgc 3’  
  
Construct shRNA [GOLGB1.3]  
  
GOLGB1.3(+) [58 nt] : 
5’ CCGGgcactgaacatcaaagtagaaCTCGAGttctactttgatgttcagtgcTTTTTG 3’  
GOLGB1.3(-) [58 nt] :  
5’ AATTCAAAAAgcactgaacatcaaagtagaaCTCGAGttctactttgatgttcagtgc 3’  
Forward oligo :  
 
5’ CCGGxxxxxxxxxxxxxxxxxxxxxCTCGAGxxxxxxxxxxxxxxxxxxxxxTTTTTG     3’  
 
Reverse oligo :  
 
3’     xxxxxxxxxxxxxxxxxxxxxGAGCTCxxxxxxxxxxxxxxxxxxxxxAAAAACTTAA 5’ 
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20 min, 75°C for 20 min, 70°C for 20min, 65°C for 20 min, and 40°C for 60 min. The 
annealed oligos can be stored at -20°C for several months. 
The pLKO.1 vector was next prepared for cloning. First, 1 µg of vector was 
digested with AgeI and EcoRI (New England Biolabs) restriction enzymes at 37°C for 3.5 
hr. The digested plasmid was run on a 0.8% agarose gel and the 7 kb band was purified 
by gel extraction using the QIAquick gel extraction kit (QIAGEN). Purified DNA was 
quantified and prepared for ligation. 50 ng of digested pLKO.1 was combined with 2 uL 
of diluted (1:10 in water) annealed oligo, 1 uL of T4 DNA ligase (New England 
BioLabs), 2 uL of 10 X T4 DNA ligase buffer, and water to a final volume of 20 uL. The 
ligation was incubated at 16°C overnight. The next morning, 1-3 uL of the ligation was 
transformed into 25 uL XL10-gold ultracompetent cells (Strategene) by electroporation. 
The transformation product was plated on an agarose plate containing 100 ug/mL 
ampicillin and incubated at 37°C overnight. The following day, 3-5 colonies from each 
transformation were picked and incubated with 3 mL of LB+ ampicillin shaking 
overnight at 37°C. A mini prep (QIAGEN) was performed on 1.5 mL of the bacterial 
suspension and the remaining volume was stored at 4°C. DNA from the mini-prep was 
sent for sequencing with pLKO primers: 
forward: 5’ TGGACTATCATATGCTTACCGTAAC 3’ 
reverse : 5’ GTATGTCTGTTGCTATTATGTCTA 3’  
After the sequence was confirmed, a maxi-prep (QIAGEN) was performed on the 
remaining bacteria and DNA was quantified.  
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Lentiviral production. The day before transfection (Day 1), 293FT cells were plated in a 
10 cm tissue culture plate so that they would be 90-95% confluent the following day (2.5 
- 5 x 106 cells in 10 mL of growth medium containing 10% FBS and no antibiotics).  On 
the day of transfection (Day 2), the culture medium was removed and replaced with 6 mL 
of medium containing serum. DNA-Lipofectamine complexes were prepared for each 
construct. Briefly, in a sterile 5 mL tube, 11 µg of lenti vector was added to packaging 
vectors (1.8 µg of REV, 4.5 µg of PAK, and 2.7 µg of ENV (20 µg total)) in 1.5 mL of 
medium without serum and antibiotics. In a separate sterile 5 mL tube, Lipofectamine 
2000 (Life Technologies) was mixed gently before use and then diluted 50 ul in 1.5 mL 
of medium without serum and antibiotics. The mixture was incubated for 5 min at RT. 
Following the 5 min incubation, the diluted DNA was combined with the Lipofectomine 
2000, gently mixed, and left to incubate for an additional 20 min at RT to allow DNA-
Lipofectamine complexes to form. Complexes were added drop-wise to each dish of cells 
and mixed gently by rocking back and forth. Cells were incubated overnight at 37°C in a 
humidified 5% CO2 incubator. The next day (Day 3), the medium containing DNA-
Lipofectamine 2000 complexes was removed and replaced with 6 mL fresh complete 
culture medium without antibiotics. Cells were incubated overnight again at 37°C in a 
humidified 5% CO2 incubator for virus particles to assemble. The supernatant containing 
virus was harvested 48-72 hr post transfection (Days 4-5) simple by removing medium 
and storing in a 15 mL capped conical tube. Because the virus was infectious at this 
stage, extra precautions were taken. Supernatant was centrifuged at 3,000 rpm for 15 min 
at 4°C to pellet cell debris. The supernatant was then filtered through a Millex-HV 0.45 
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um polyvinylidene fluoride filter (Millipore) and separated into 1 mL aliquots. Unused 
stocks were stored at -80°C.  
 
Lentiviral infection. For lentiviral infection, adherent cells were seeded at a 
concentration of 1 x 106 cells/well (final volume per well was 2 mL) in 6 well plates 1 
day prior to infection. Cells were allowed to incubate overnight (37°C, 5% CO2). The 
next day, media was removed and 1 mL of lentivirus containing polybrene at a final 
concentration of 2 ug/mL was added to each well. Polybrene, a small positively charged 
molecule, was added to neutralize the charge repulsion between virions and molecules on 
the cell surface to allow for more efficient infection. Cells and virus were incubated 
overnight (37°C, 5% CO2). 24 hr after infection, media was changed and replaced with 
fresh media containing puromycin (5 ug/mL) to select for infected cells. Cells were 
incubated in media and puromycin (37°C, 5% CO2) to allow for induction of the shRNA 
and fresh media was added as needed. In order to observe phenotypic changes to cells 
following infection with virus containing targeted and non-targeted shRNA, light field 
microscopy was used to image cell morphology at time points following puromycin 
selection. Furthermore, cells were harvested and protein extraction and Western blot 
analysis was performed in order to confirm silencing of the target protein and examine 
the expression of several other proteins. 
 
Cell proliferation and adhesion. HEP3B cells were incubated with a shRNA lentivirus 
targeting the GOLGB1 gene (shRNA GOLGB1.1). After 24 hr incubation at 37°C, 5% 
CO2 with the virus, cells were selected for viral integration by a 48 hr incubation with 
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puromycin. Cells were then split and plated on 96 well tissue culture E-Plates with micro-
electrodes integrated on the bottom (Roche) at 104 cells per well. The Roche 
xCELLigence machine which measures electrical impedance in real time as cells attach 
and grow on E-plates was programmed to take measurements every minute for 48 hr.  
 
Statistical analysis. Statistical calculations were performed with InStat (GraphPad 
Software) and data values are expressed as means ± standard error of the mean from 
experiments performed at least in triplicate. For TMA data plots, the box extends from 
the 25th to 75th data percentile, the line represents the data median, and the whiskers mark 
the minimum and maximum data boundaries. P-values of less than 0.05 were considered 
statistically significant. 
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CHAPTER 3: RESULTS 
 
3.1  High-throughput combinatorial peptide screen in a cancer patient  
Vascular mapping allows for the opportunity to identify molecular markers 
specific to different tissues. We performed a combinatorial peptide screen on a 53 year-
old male patient (patient 6) who presented with HCC and clear cell renal cell carcinoma, 
the most common type of renal cell carcinoma (RCC).  Multiple primary tumors were 
found in the liver indicating that the HCC was multifocal. Immunohistochemical analysis 
of the HCC and RCC tissue sections from patient 6 determined that both specimens 
represented independent primary tumors (Fig. 3-1). Hep Par 1 expression was positive in 
HCC tissue sections but negative in the RCC tissue sections, indicating distinct primary 
tumors [79]. The Pax8 marker is used to identify both primary RCC as well as metastatic 
RCC [80]. Pax8 staining was solely positive in RCC tissue sections, further confirming 
the tumors were independent in origin. 
A large-scale preparation of CX7C and CX8C phage random peptide libraries was 
administered into the patient once he had been formally declared brain dead according to 
ethical guidelines. Thirty-minutes post-infusion, tissue biopsies (Table 3-1) were 
collected including two samples from the HCC tumor. Autopsy samples (Table 3-2) were 
also collected following 72 hr of systemic phage circulation. DNA was extracted from 
each tissue and phage were amplified by PCR using primers containing a tag specific to 
the tissue of origin. Amplicons were sequenced using the Roche 454 FLX platform (Fig. 
3-2a) that can deliver reads of up to 1,000 basepairs with a typical overall throughput of  
  
 Fig. 3-1. Pathological analysis of a patient with HCC and RCC. 
Immunohistochemistry was performed on HCC and RCC tissue specimens obtained from 
patient 6. HCC tissues were stained with antibodies against Hep Par 1 and Pax
tissue was stained with antibody against Pax
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Table 3-1. Recovered peptide containing sequences from patient biopsy tissue 
samples in a high-throughput phage display screen. Total peptide containing 
sequences, number of different peptide containing sequences and the percentage of 
different peptide containing sequences are shown. 
Tissues 
Total peptide 
containing 
sequences 
Different peptide 
containing 
sequences 
% 
Different 
Bone marrow 134,679 122,440 90.91 
Liver (normal) 28,574 16,602 58.1 
Liver Tumor 1 60,444 24,793 41.02 
Liver Tumor 2 21,239 19,508 91.85 
Muscle 17,808 16,621 93.33 
Prostate 45,544 30,359 66.66 
Skin 93,025 29,669 31.89 
White adipose 
tissue 
28,574 16,602 58.1 
Yellow bone 
marrow 
27,462 18,886 68.77 
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Table 3-2. Recovered peptide containing sequences from patient autopsy tissue 
samples in a high-throughput phage display screen. Total peptide containing 
sequences, number of different peptide containing sequences and the percentage of 
different peptide containing sequences are shown. 
Tissues 
Total peptide 
containing 
sequences 
Different peptide 
containing 
sequences 
% 
Different 
Adrenal gland 22,793 13,855 60.79 
Aorta - ascending 12,000 6,985 58.21 
Aorta – thoracic 21,253 11,518 54.19 
Bladder 22,334 12,676 56.76 
Cerebellum 21,717 13,067 60.17 
Cerebrum 22,266 13,516 60.7 
Coronary artery 
(left) 
10,022 6,418 64.04 
Duodenum 21,213 11,975 56.45 
Dura mater 21,333 12,211 57.24 
Esophagus 18,570 11,374 61.25 
Gall bladder 13,792 9,214 66.81 
Heart – infarcted 21,239 11.996 56.4 
Heart – normal 13,368 8,399 62.8 
Kidney-normal 19,010 12,547 66 
Kidney- tumor 1,479 958 64.8 
Large bowel 13,594 8,965 65.95 
Liver 99,373 36,860 37.09 
Liver tumor 1 31,941 25,749 80.61 
Liver tumor 2 13,063 8,291 63.47 
Lung 13,525 9,117 67.41 
Lung– lower right 
lobe 
16,864 10,545 62.53 
Lymph node 118,670 84,080 70.85 
Muscle 24,229 14,365 59.29 
Pancreas 14,790 9,167 61.98 
Prostate 15,654 8,261 52.77 
Skin 23,861 14,211 59.56 
Small bowel 46,660 29,146 62.46 
Spleen 22,085 19,040 86.21 
Stomach 12,682 7,650 60.32 
Testis 15,707 9,704 61.78 
Thyroid 23,787 13,103 55.08 
White adipose tissue 16,708 10,881 65.12 
 
  
a. 
b. 
 
Fig. 3-2. Schematic of phage DNA amplification from human tissue and resulting 
amplicon layout. a)Phage DNA located in patient tissue were amplified using sequence 
specific primers with a tag added to the 5’ end of the forward primer or three nucleotide 
tag added to the 5’ end of the forward and reverse primers. Following amplification, 
amplicons from all tissues were pooled, 454 adaptor sequences were ligated to each end 
of the amplicon and sequencing was performed. b) Recovered sequences contained the 
index tag indicating the tissue of origin, flanking regions of fUSE5 vector, and the DNA 
sequence encoding a CX7C or CX
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8C insert. 
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450 megabases for amplicon sequencing. For phage display applications, over 1 million 
sequences per run can be generated using this sequencing platform. 
A system for online uploading and processing of raw sequencing data was 
designed using PERL scripts and a MySQL relational database management system in 
collaboration with Dr. Nalvo Almeida (Virginia Bioinformatics Institute, Virginia 
Polytechnic University; current address: School of Computing, Federal University of 
Mato Grosso do Sul) and Dr. Joao Setubal (Virginia Bioinformatics Institute, Virginia 
Polytechnic University; current address: Department of Biochemistry, University of San 
Paulo). (Fig. 3-3, 3-4). Raw sequencing and quality compressed data files were uploaded 
to the phage system and passed to a process engine that confirmed the presence of a 
peptide insert as well as a tag identifying the tissue of origin for each sequence (Fig 3-
2b). Filters with varying stringency recognizing sequence match were employed to 
maximize data recovery. Identified peptides were separated by tissue of origin then 
passed through a quality score filter. Only reads containing quality scores with a > 95% 
confidence in the sequence region encoding the displayed peptide were uploaded to the 
database. 
The database of recovered peptides was compiled and published online as an 
application that enabled users to search for specific peptide sequences (Fig. 3-5), examine 
the distribution of sequences (Fig. 3-6, 3-7), and identify peptide sequences that are 
exclusively present in tissues of interest and not in other tissues (Fig. 3-8). This system 
allows for a single multi-functional program for easy lab member access and analysis of 
newly acquired data.  
  
 Fig. 3-3. Schematic of raw data processing and database construction for sequencing 
data recovered from high-throughput phage display screens. 
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 Fig. 3-4. Screenshot of user interface for online database of high
display screening data. Users are 
and tissue. The ability to upload new data for processing is also included.
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-throughput phage 
able to search by keyword, peptide sequence, run ID, 
 
 
 
 Fig. 3-5. Output of peptide search function using newly designed online database for 
high-throughput phage display screeni
listed as well as the DNA sequence, tissue of origin, PCR tag, location within the raw 
sequencing data file, filter passed, and quality acceptance for each peptide.
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ng data. The peptides matching the search are 
 
  
 
Fig. 3-6. Run ID search for online databas
screening data. Number of sequences and number of peptides are reported as an 
overview. The filter by which each peptide was identified is included. A table of the total 
and good quality peptides recovered from each tissu
view all recovered peptide sequences is also available.
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e of high-throughput phage display 
e in the run is also given. Options to 
 
 
 Fig. 3-7. Tissue search for online database of high
screening data. Number of peptides and the filter by which each peptide was identified 
are reported as an overview. Options to view recovered peptide sequences from the 
searched tissue is also available. The option to calculate a saturation curve using the data 
recovered from the searched tissue is included.
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-throughput phage display 
 
 
                
 
 
Fig. 3-8. Advanced Tissue search for online database of high
display screening data. The input matrix (left) allows users to include or exclude tissues 
from which to search for unique peptides. The term unique peptide is defined as a peptide 
that is only found in included tissues but not in excluded tissues. The option to remove 
datasets such as peptides recovered from sequenced library is available. An example of 
the search results for unique peptides only found in biopsy bone marrow and autopsy 
yellow bone marrow samples are shown (right). The number of times the peptide is found 
is included as well as the number of sequences that passed the quality filter.
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-throughput phage 
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We created saturation plots that depict the number of unique reads against the 
total number of sequences (Fig. 3-9). Analysis of large-scale derived sequences (a total of 
1,242,931 sequences distributed among 41 samples, Table 3-1, 3-2, 3-3) elucidated a 
non-random distribution of peptides among tissues (Fig. 3-9). In the data recovered from 
each tissue, the number of unique sequences stabilized as the number of total sequences 
increased. This finding confirmed the feasibility of this methodology for the isolation of 
selective peptides targeting normal and diseased organs (Fig. 3-9). Furthermore, for the 
sequenced library, the number of unique sequences increased linearly with the number of 
total sequences recovered, demonstrating that the initial library was informative and not 
affected by sequence artifacts that may arise during preparation and recovery. 
 
3.2  Bioinformatic selection of tissue specific peptides 
 Advanced bioinformatics tools are essential for efficient processing and 
identification of tissue specific peptide motifs. In our study, millions of peptide sequences 
were recovered utilizing next-generation sequencing technology. The recovered data set 
was subjected to multiple levels of stringent bioinformatic analysis to more effectively 
select for significantly enriched motifs in tissues of interest. In an initial analysis, 
peptides were clustered into four amino acid long motifs to identify peptides that were 
significantly enriched in HCC samples (workflow represented in Fig 2-2). From this data 
set, 113 peptides were determined to be specific to four samples of human HCC tumor 
tissue that were recovered including two samples during biopsy and two samples during 
autopsy. In the two recovered autopsy samples, 10 and 20 peptides were selected from 
top motifs while in the biopsy samples, 15 and 12 peptides were selected (Table 3-4a).  
 
 Fig. 3-9. Saturation curves for peptide sequences recovered from human liver and 
HCC autopsy samples following a high
curve for CX7C library is also included. In the graphs, the total number of sequences 
versus the number of different sequences is shown.
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-throughput phage display screen. 
 
 
 
Saturation 
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Table 3-3. Overview of recovered peptide containing sequences from high-
throughput phage display screen in a cancer patient. All 40 tissues were compiled and 
sequencing results from naïve, uninjected CX7C and CX8C libraries are included. Total 
peptide containing sequences, number of different peptide containing sequences and the 
percentage of different peptide containing sequences are shown. 
Tissues 
Total peptide 
containing 
sequences 
Different peptide 
containing 
sequences 
% 
Different 
41 total 1,242,931 759,340 61.09 
CX8C library 77,888 73,906 94.89 
CX7C library 81,458 77,462 95.09 
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Table 3-4. Tissue-specific peptides selected from liver tumor tissue. a) Peptides 
specific to single tissues. b) Peptides specific to multiple tissues. c) Lead peptide 
sequences selected from liver tumor tissues. Peptide in red was selected for further 
biochemical validation. 
a.  
Single tissue specific peptides 
Sample Peptides selected 
HCC- autopsy sample 1 10 
HCC- autopsy sample 2 20 
HCC- biopsy sample 1 15 
HCC- biopsy sample 2 12 
 
b. 
Multi-tissue specific peptides 
Sample 1 Sample 2 Peptides selected 
HCC- autopsy sample 2 HCC- autopsy sample 1 9 
HCC- autopsy sample 2 HCC- biopsy sample 1 23 
HCC- autopsy sample 2 HCC- biopsy sample 2 6 
HCC- autopsy sample 1 HCC- biopsy sample 1 5 
HCC- autopsy sample 1 HCC- biopsy sample 2 5 
HCC- biopsy sample 1 HCC- biopsy sample 2 8 
c. 
Selected Peptide Sequences 
RIHSSAYR (liver tumor aut2) 
LHTRYRLS (liver tumor aut2) 
SGATPPVR (liver tumor aut2) 
VEMSARS (liver tumor aut2) 
LSNVPSRT (liver tumor aut2) 
LRCMSPT (liver tumor aut1) 
RGPVSGY (liver tumor aut1) 
RSDLKGFS (liver tumor aut1) 
SGVGAASL (liver tumor bio1) 
AVRGGGPV (liver tumor bio1) 
PERARREI (liver tumor bio1) 
PGAGSVKV (liver tumor bio2) 
ARVIPRA (liver tumor bio2) 
SMLRSER (liver prim bio2) 
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Furthermore, multiple HCC samples were combined into correlative groups and peptides 
found in top motifs were selected (Table 3-4b). From the 57 single tissue-specific 
peptides reported in Table 3-4a, 14 peptides were selected based on qualitative analysis 
including the omission of peptides containing tryptophan, RGD, and NGR in their 
sequence (Table 3-4c). RGD and NGR sequences were excluded as these are well 
described tumor vasculature specific tri-peptide motifs [81, 82]. The peptide, 
SGVGAASL, clustered to the motif GAAS, was selected for biochemical validation and 
characterization as an HCC targeting peptide in Chapter 3.3.  
 
3.2.1 Generation of amino acid substitution matrices 
After an initial bioinformatics analysis, a more comprehensive study was 
performed to account for multidimensional properties of amino acids including 
bioinformatic (1D), physiochemical (2D), structural and pharmacophoric (3D), and 
“druglike” properties (workflow represented in Fig 2-3).  
The 1D clustering algorithm was developed by adapting the BLOSUM62 amino 
acid substitution matrix. Values in the BLOSUM62 matrix are based on examination of 
the probability of amino acid substitution in aligned related proteins [50]. A similarity 
matrix comparing each amino acid was generated and a three dimensional PCA was 
performed to cluster amino acids into substitution groups (Fig. 3-10a,b). The substitution 
matrix derived from the BLOSUM62 analysis is shown in Table 3-5a.  
In addition to a bioinformatics approach, amino acids were grouped based on the 
physiochemical properties including size, charge, hydrophobicity/hydrophilicity, and  
  
 a. 
b. 
Fig. 3-10. BLOSUM62 analysis for amino 
20 amino acids (abbreviated in single letters) b) Principal component analysis performed 
on BLOSUM62 similarity matrix. Three components were used. R
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acid substitution. a) similarity matrix for all 
2
=0.68, Q2=0.35.  
 Table 3-5. Amino acid substitution matrices.
acid characteristics, c) ROCS, d) ChemGPS
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 a) BLOSUM62, b) 2-dimensiona
-4D, e) ChemGPS-9D 
 
l amino 
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aromaticity (Table 3-6). Based on these molecular properties, seven groups were 
qualitatively identified (Table 3-5b).  
Next, structural and pharmacophoric properties were considered using the ROCS 
software where each property was given a score between 0-1 (0 indicating dissimilarity 
and 1 indicating similarity) [76]. The combined scores were used to generate a similarity 
matrix with a value of 2.0 representing maximum similarity with regards to the two 
examined properties (i.e. the same amino acid) (Fig. 3-11a). A three-dimensional PCA 
was performed to group amino acids based on the generated similarity matrix (Fig. 3-
11b) and a unique, more stringent amino acid substitution matrix was defined (Table 3-
5c).  
Finally, a previously described “drugspace” map constructed by applying 
geographical conventions such as dimensions and objects when examining a chemical 
space was used to define two additional amino acid substitution matrices (ChemGPS4 
and 9, Table 3-5d,e) [54]. Both a 4-dimensional PCA as well as a 9-dimensional PCA on 
this data was performed to group amino acids based on similarity within the “drugspace.” 
Using these unique amino acid substitution matrices, consensus motifs in tissues 
of interest can be defined by not only taking into account amino acid sequence, but also 
the many physical and biological properties influenced by motif shape and activity.  
 
 3.2.2 Selection of tissue specific peptides by multidimensional analysis 
 Using our five defined amino acid substitution matrices, an analysis of tissue 
specific motifs was performed utilizing the patient combinatorial peptide screen data. For 
each substitution matrix, identified motifs were ranked using two different scoring  
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Table 3-6. Grouping of amino acids based on 2-dimensional characteristics 
including size, charge, aromaticity, and hydrophobilicity. 
 
Amino acid Properties 
A small 
G small 
P small 
D acceptor, anion 
E acceptor, anion 
F aromatic 
W aromatic, donor 
Y aromatic, donor, acceptor 
C hydrophobic 
I hydrophobic 
L hydrophobic 
M hydrophobic 
V hydrophobic 
H donor, acceptor 
N donor, acceptor 
Q donor, acceptor 
K donor, cation 
R donor, cation 
S donor, acceptor, small 
T donor, acceptor, small 
  
 a. 
b. 
Fig. 3-11. ROCS scoring based amino acid substitution analysis.
for all 20 amino acids (abbreviated in single letters) based on ROCS scoring of similarity 
between amino acid shape and pharmocophoric properties. b) Principal component 
analysis performed on ROCS derived similarity matrix. Three components were used. 
R2=0.73, Q2=0.41.  
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 a) Similarity matrix
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algorithms: one placing greater weight on peptide frequency within a motif (simple 
score), and one placing greater weight on peptide diversity within a motif (combined 
score). The top 100 motifs were identified using each amino acid substitution matrix and 
each pattern ranking score resulting in a total of 1,000 top ranked motifs for each tissue 
recovered from our patient screen. The top motifs identified in these analyses as well as 
the number of unique peptides clustered to those motifs are shown in Tables 3-7 through 
3-16. Tables include the maximum score (simple or combined) of the top motif in each 
tissue as well as an example peptide of that motif. In tissues with high recovered peptide 
diversity such as bone marrow and lymph node, the score of the top motif was 
consistently less than tissues where a lower diversity of peptides were recovered (i.e. 
prostate and skin). In particular, the top motifs selected from peptides recovered in liver 
tumor tissue had some of the highest simple and combined scores, indicating that 
selection of peptides occurred in this tissue and further establishing the potential of these 
motifs for specificity to tumor vascular beds. Examination of peptides clustering to top 
motifs across all 10 analyses identified a subset of common peptides (Table 3-17). 
Common peptides selected in analyses using the simple score ranking are shown in Table 
3-18 and using the combination score ranking in Table 3-19. Peptides identified in 
multiple analyses may lead to an increase in confidence regarding targeting specificity 
and significance in the tissue of interest. 
 To further prioritize top scoring motifs selected in liver tumor tissue, PepBank 
software was used to identify biologically relevant peptides [83]. Peptides sharing 
sequence homology to hormone proteins are listed in Table 3-20 with the relevant 
sequence matching to selected liver tumor specific motifs shown in bold. A functional  
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Table 3-7. Summary of motif selection analysis performed using the BLOSUM62 
amino acid substation matrix and simple score ranking for all patient tissues 
recovered. 
BLOSUM62 Simple Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 217 SFCRGLG 0.284 GVGRCYP 
Aorta 124 RSFAFLR 0.475 QMFTWSR 
Bladder 196 RFDLRLL 0.478 VMRVEYRC 
Bone Marrow 3938 RLFGxFL 0.091 RMYGSFLG 
Bowel 302 ARSAxLDA 0.378 TRPAPLET 
Brain 250 SRDGADR 0.389 PREGTEQ 
Coronary Artery 144 DFFLALA 0.589 EFFIAVT 
Duodenum 250 DFRGRFA 0.489 AFRGRFE 
Duramater 207 RADFSD 0.452 RARAEYSE 
Esophagus 195 LRRxHxxH 0.453 HTLHNRRV 
Fat 319 RLLHLDR 0.425 RVLHVNR 
Gallbladder 168 RLRSGRL 0.357 LRGSRMQF 
Heart 232 SSDxSRLL 0.538 SSNDPRLL 
Kidney 201 RRCSCGL 0.297 MGCPCQR 
Liver 549 LGLRCCC 0.245 CCCRVGL 
Liver Tumor 235 SFRRAA 0.573 ATKRWPTH 
Lung 325 DARSFSA 0.460 EARPWST 
Lymph Node 676 HxxLLxLD 0.160 HDGLLNME 
Muscle 227 SxCRFRL 0.342 SVCRFRL 
Pancreas 216 HLFLALG 0.458 GVTVWLH 
Prostate 168 GAAFFSD 0.616 DSYWATG 
Skin 191 LxACCDL 0.389 VDCCAIV 
Spleen 280 GAxFAxC 0.410 CETWNAGT 
Stomach 369 LASAxRAL 0.509 LTRLAPAV 
Testis 188 RxLLRGSG 0.358 GSGQILAR 
Thyroid 257 DRDxxFFD 0.330 EYYAGERE 
Yellow Bone Marrow 632 SFGDLAD 0.265 GNTLEGWS 
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Table 3-8. Summary of motif selection analysis performed using the BLOSUM62 
amino acid substation matrix and combination score ranking for all patient tissues 
recovered. 
BLOSUM62 Combo Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 183 SFCRGLG 0.043 GVGRCYP 
Aorta 114 LxSLLCL 0.112 MCLVSVMS 
Bladder 192 RGDASFF 0.076 RGDTSWY 
Bone Marrow 2501 LRLxDLF 0.016 LKVRELFS 
Bowel 391 DxRRFGA 0.096 AGFRRWD 
Brain 145 SDRRSSDR 0.085 RNSSRRDS 
Coronary Artery 173 CxSLFxC 0.133 CLYVSYC 
Duodenum 180 RAxGGLxG 0.082 GVIGGITR 
Duramater 157 FxHxRGxD 0.109 WFHARGLE 
Esophagus 223 SGxSARxL 0.094 PGHPAQEL 
Fat 652 LLGALCG 0.127 RGCLAGLV 
Gallbladder 212 SDRFxLLL 0.098 SERYTVLL 
Heart 158 RDxRGCL 0.129 RDWRGCV 
Kidney 228 DDRxDAD 0.062 EEREDAEL 
Liver 864 FRxAFSD 0.031 ESYARRF 
Liver Tumor 979 RxGLxGSA 0.162 QVGLGGST 
Lung 102 SDxDGxxD 0.126 SDADGMQD 
Lymph Node 1849 DxLFARA 0.018 ARAWIKDR 
Muscle 857 LRxFSLxA 0.106 MRHFPMPT 
Pancreas 157 LGLCGSAA 0.098 ATSGCVGV 
Prostate 305 GAxFFSD 0.241 DSYWGAG 
Skin 386 SFxDGRA 0.068 AAQGNDFP 
Spleen 644 SSLLAxF 0.087 FIAILSS 
Stomach 176 SFGGAxF 0.133 WPAGGYS 
Testis 177 RxCRAGD 0.059 WRGCQAGN 
Thyroid 235 RFGFRDRA 0.046 TRERFGWR 
Yellow Bone Marrow 861 SxSDGSF 0.074 SFPGDPRS 
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Table 3-9. Summary of motif selection analysis performed using the 2-dimensional 
properties amino acid substation matrix and simple score ranking for all patient 
tissues recovered. 
2D Simple Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 285 LRRFNLRF 0.260 LRKWNVRW 
Aorta 282 RSFSFxN 0.474 QMFTWSR 
Bladder 269 RFDLRLL 0.472 VMRVEYRC 
Bone Marrow 3909 SFLSFA 0.096 TAFSVFS 
Bowel 499 SxAAALDS 0.378 TRPAPLET 
Brain 348 NDAADRA 0.396 AREGGEND 
Coronary Artery 310 NFFLSLA 0.578 QWYVSVGE 
Duodenum 285 NDAAAASL 0.450 VSPAGAEN 
Duramater 250 SANRNAS 0.421 TANRQGSQ 
Esophagus 297 SALLLLRF 0.391 TALMIVRW 
Fat 408 RxNxxNFL 0.418 RFQELQFV 
Gallbladder 233 NLRSARL 0.368 LRGSRMQF 
Heart 314 SSNDARL 0.534 VLRGEHSS 
Kidney 337 RSAAxNLD 0.308 EVNMAPSR 
Liver 1028 RDDARLL 0.220 REDGRVLN 
Liver Tumor 349 SSxRFxDS 0.515 SEWWRRST 
Lung 275 SSFARAD 0.458 EARPWST 
Lymph Node 1232 NRxLLSLD 0.163 QRRMLTMD 
Muscle 525 NxRFRLL 0.325 VIRFRCH 
Pancreas 183 NLFLSLA 0.440 QIYVSIG 
Prostate 388 DSFFAAA 0.605 DSYWGAG 
Skin 320 SxxSALNR 0.375 KQVASSAS 
Spleen 450 ASAFSALA 0.404 GTPWTGCG 
Stomach 441 LSAALNAL 0.506 CTGGCQAL 
Testis 179 RALLNxSA 0.353 GSGQILAR 
Thyroid 294 RDAxFFD 0.341 REAGWYEM 
Yellow Bone Marrow 568 SFxLADDA 0.267 GEEAVVYT 
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Table 3-10. Summary of motif selection analysis performed using the 2-dimensional 
properties amino acid substation matrix and combination score ranking for all 
patient tissues recovered. 
2D Combo Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 208 LRRFNLRF 0.039 LRKWNVRW 
Aorta 221 RAASSANA 0.096 KGATTGHG 
Bladder 210 ALxANFLA 0.071 PVWQGRVP 
Bone Marrow 2494 SxDRNF 0.015 SWHREIT 
Bowel 498 LLARSNA 0.105 APNTRAVL 
Brain 160 NSAxSFD 0.091 AQSGLTWE 
Coronary Artery 260 LLLAAALD 0.120 ECPGGCMV 
Duodenum 297 DDNSAxxA 0.070 DDQSATLG 
Duramater 177 DRDRxAND 0.093 ERERLGHE 
Esophagus 303 RASFNDA 0.074 PEHWSAKR 
Fat 580 NAxSRSA 0.112 PPTKSPAH 
Gallbladder 196 SDRFxLLL 0.098 SERYTVLL 
Heart 214 LAxALNFA 0.169 GFQLGGGL 
Kidney 219 RxSALRDN 0.056 QDRLASTR 
Liver 833 RxAxNLNN 0.029 RRGHQVNN 
Liver Tumor 1001 RxFxLNNA 0.191 RYWGLHHA 
Lung 209 RARxDDxL 0.114 RARNEEGI 
Lymph Node 1734 LFSDAA 0.018 GPESFLRV 
Muscle 921 DARLAxLA 0.100 GMRAVRAE 
Pancreas 139 SDFxAxFA 0.091 GFRGRWDT 
Prostate 501 LSxFLDF 0.231 SWDMFDSI 
Skin 417 RxFxAARF 0.062 RGFFAGRF 
Spleen 871 RLNxxASN 0.115 RLNSLGSQ 
Stomach 194 LSADRxLL 0.090 VSGDKGVV 
Testis 215 SSFDRxR 0.071 MTSWDKYR 
Thyroid 206 RRLLLSNL 0.046 RRLVITNV 
Yellow Bone Marrow 746 RAFAxLxD 0.076 RAYGFVGD 
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Table 3-11. Summary of motif selection analysis performed using ROCS derived 
amino acid substation matrix and simple score ranking for all patient tissues 
recovered. 
ROCS Simple Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 152 VPDPNxS 0.295 VPDPQIS 
Aorta 120 RxFSFLN 0.475 QMFTWSR 
Bladder 143 RFDLRLL 0.484 LLRLDWR 
Bone Marrow 3684 PVRSxxL 0.100 PVRSLEMG 
Bowel 150 FVVVPxA 0.446 AKPIVVWA 
Brain 107 PRxGADN 0.398 PREGAEQ 
Coronary Artery 181 NFFLxLA 0.594 NYFLTLA 
Duodenum 118 DFRGxFA 0.490 AFRGRFE 
Duramater 147 SSxVGGA 0.462 SSSIGGA 
Esophagus 218 SxLxVVRF 0.391 TALMIVRW 
Fat 302 NNSxxFL 0.432 ANNSPGWL 
Gallbladder 315 VRGSRVN 0.413 QVRSGKV 
Heart 194 SxNxPRxL 0.538 SSNDPRLL 
Kidney 148 RNLPLGL 0.297 MGCPCQR 
Liver 663 SxLxSPA 0.248 GAPSRLRS 
Liver Tumor 169 SSxRFxDS 0.515 SEWWRRST 
Lung 214 SSFPxAD 0.460 EARPWST 
Lymph Node 505 RxDVxSVD 0.156 EVTNVEDH 
Muscle 204 FLSxRRD 0.312 ERRLSLYS 
Pancreas 179 RLFVSVG 0.455 GVTVWLRR 
Prostate 192 DSFFAA 0.610 VESFWAAS 
Skin 165 VVALLDV 0.418 VDCCAIV 
Spleen 323 GxPFSGxG 0.414 GFGSWPSG 
Stomach 160 VANxxPxL 0.512 LTPAVQAV 
Testis 86 GLGALDRD 0.390 ERELAGLG 
Thyroid 129 DRDxxFFD 0.330 EYYAGERE 
Yellow Bone Marrow 338 VSxxxGNS 0.286 SQGARRSV 
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Table 3-12. Summary of motif selection analysis performed using ROCS derived 
amino acid substation matrix and combination score ranking for all patient tissues 
recovered. 
ROCS Combo Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 111 VSLxLLL 0.044 WLLLDMSI 
Aorta 129 VxxVVLxD 0.126 EWMVVLGV 
Bladder 127 PVxGNFVP 0.074 PVWQGRVP 
Bone Marrow 2431 RxDxDVF 0.020 REDPDVYT 
Bowel 302 SxLPAPR 0.096 VTRLPAPR 
Brain 135 SDRRSSxR 0.081 SDRRTSLR 
Coronary Artery 127 RVLAGLG 0.136 RVCAGLG 
Duodenum 87 VAAFPG 0.074 VAAYPGA 
Duramater 246 DRGxRDRD 0.088 ERERLGHE 
Esophagus 97 VNxxxVGN 0.078 VQLGQIGN 
Fat 566 SxAVxDP 0.148 GSRAVMEP 
Gallbladder 189 SDRFxVLL 0.098 SERYTVLL 
Heart 136 RxVSVVR 0.154 SRVVSVER 
Kidney 239 VLLNxVL 0.060 LLVLNLLV 
Liver 838 GSVARF 0.033 GTVARFC 
Liver Tumor 1027 RxFxVxNG 0.164 KGYLIGNG 
Lung 137 RxxNRDP 0.150 PDRNSRRV 
Lymph Node 1679 VLFGAR 0.019 KVLYGARS 
Muscle 978 VSxAxDG 0.114 VSTAREGS 
Pancreas 101 VGVLGxSA 0.098 ATSGCVGV 
Prostate 297 VVNxxRSV 0.255 VVQEGRSI 
Skin 180 PRSRVL 0.056 LPRSHVLL 
Spleen 641 VVRNSL 0.139 YIIRQSLD 
Stomach 116 ARxFxxDA 0.118 AESFWLRA 
Testis 105 GLGALDRD 0.080 ERELAGLG 
Thyroid 176 VNSVVLRR 0.046 RRLVITNV 
Yellow Bone Marrow 780 SDxPxVG 0.101 SEPPRVGR 
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Table 3-13. Summary of motif selection analysis performed using ChemGPS-4D 
amino acid substation matrix and simple score ranking for all patient tissues 
recovered. 
ChemGPS-4D Simple Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 155 VPNPNVS 0.295 VPDPQIS 
Aorta 209 RSFSFVN 0.475 QMFTWSR 
Bladder 169 VVRVNFR 0.458 AHFDVRIV 
Bone Marrow 3463 SFVSFA 0.099 TAFSVFS 
Bowel 252 FVVVPxA 0.410 WVMMPLGR 
Brain 267 PRNAANN 0.397 PRNGAQDS 
Coronary Artery 211 NFFVSVA 0.566 QWYVSVGE 
Duodenum 241 FxPSFC 0.453 FGPTFCL 
Duramater 247 VRVVAVRS 0.433 SRMGIMRV 
Esophagus 249 SxVVVVRF 0.391 TALMIVRW 
Fat 442 FRRSACF 0.406 FRRSGCF 
Gallbladder 230 VKASRVN 0.405 RDVRTGKL 
Heart 298 VxRPNxSS 0.538 SSNDPRLL 
Kidney 237 VRNNVxAV 0.313 VREDVRAI 
Liver 657 VAVRCC 0.248 VGLRCCL 
Liver Tumor 281 SSxKxSNS 0.526 TTRKFSDT 
Lung 265 SSFPRAN 0.455 EARPWST 
Lymph Node 1137 RxNxVSVN 0.154 QVTLKQAR 
Muscle 209 VFKVAS 0.348 TGLKFLRQ 
Pancreas 171 VRVNAAFA 0.436 GWAGEMRI 
Prostate 183 NSFFAAA 0.596 TNSFYGAA 
Skin 245 VVACCNV 0.418 VDCCAIV 
Spleen 365 AxxFxACA 0.407 ARLWDGCG 
Stomach 320 VSPAxNAV 0.509 VTPALEAL 
Testis 180 RVPRxPxA 0.361 GSPSRPLR 
Thyroid 232 NRNAxFFN 0.329 QWFAADRE 
Yellow Bone Marrow 500 NxxNVRxF 0.272 YRRVEAGD 
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Table 3-14. Summary of motif selection analysis performed using ChemGPS-4D 
amino acid substation matrix and combination score ranking for all patient tissues 
recovered. 
ChemGPS-4D Combo Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 129 PFCRAVA 0.043 GVGRCYP 
Aorta 170 SANAARAN 0.136 QGRAGNAS 
Bladder 136 PVxANFVP 0.074 PVWQGRVP 
Bone Marrow 2335 VAASSxxN 0.018 VGATTGLQ 
Bowel 423 SxVPAPR 0.080 VTRLPAPR 
Brain 147 SNRRSSNR 0.085 RNSSRRDS 
Coronary Artery 102 RVARCRAP 0.127 RMAHCRAP 
Duodenum 155 VSFRVAxS 0.073 SSGMRFSV 
Duramater 185 NRNRxARN 0.088 ERERLGHE 
Esophagus 235 VSRPPNV 0.083 LQPPRSV 
Fat 647 VVxVNNxF 0.132 YLENLWML 
Gallbladder 180 VVVxFRNS 0.098 SERYTVLL 
Heart 187 VAxAVNFA 0.162 GFQLGGGL 
Kidney 336 NNxSxRKA 0.072 EEGTLRKG 
Liver 874 SxFARSF 0.037 YSHAYSS 
Liver Tumor 1212 SSNAVRA 0.186 SSEGLRAL 
Lung 123 CFFSAA 0.130 CGATFWCK 
Lymph Node 1772 NVNSxVF 0.016 WVVTNLED 
Muscle 1078 VPAxNxxP 0.124 IPGHDDIP 
Pancreas 110 VAVCAxSA 0.098 ATSGCVGV 
Prostate 443 SASSVxVR 0.216 TGTSLCLR 
Skin 286 FSxPKF 0.059 SSWKPESW 
Spleen 643 VxCFNxP 0.102 VCCFETP 
Stomach 140 NRSVRxC 0.088 AERSVRGC 
Testis 114 SSFNKxR 0.074 MTSWDKYR 
Thyroid 230 SRNRFAFR 0.046 TRERFGWR 
Yellow Bone Marrow 765 SRCSVxR 0.096 RMMSCRTN 
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Table 3-15. Summary of motif selection analysis performed using ChemGPS-9D 
amino acid substation matrix and simple score ranking for all patient tissues 
recovered. 
ChemGPS-9D Simple Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 116 VPDPNV 0.295 VPDPQIS 
Aorta 74 RSFSFxN 0.475 QMFTWSR 
Bladder 108 VVRVDFR 0.480 VMRVEYRC 
Bone Marrow 4006 SFVSFA 0.099 TAFSVFS 
Bowel 161 FVVVPxA 0.410 WVMMPLGR 
Brain 163 PxDAADN 0.398 PREGAEQ 
Coronary Artery 142 NFFVSVA 0.579 QWYVSVGE 
Duodenum 148 FxPSFC 0.453 FGPTFCL 
Duramater 164 VxDACAS 0.435 VVCDGCAT 
Esophagus 165 VxKxHxxH 0.440 VVKLHPRH 
Fat 233 VFxxSNN 0.417 VYTYSQQM 
Gallbladder 221 VKASRxN 0.413 QVRSGKV 
Heart 176 VVRxDNxS 0.538 SSNDPRLL 
Kidney 212 VACPCNR 0.297 MGCPCQR 
Liver 657 VAVRCC 0.249 VGLRCCL 
Liver Tumor 176 HSxxRKxA 0.531 ATKRWPTH 
Lung 175 SSFPRxD 0.460 EARPWST 
Lymph Node 584 HxDVxSxD 0.156 HSDLRTWE 
Muscle 87 VFKVAS 0.348 TGLKFLRQ 
Pancreas 139 HVFxSVA 0.453 AVSLFVH 
Prostate 108 DSFFAAA 0.616 DSYWGAG 
Skin 218 VxACCDV 0.418 VDCCAIV 
Spleen 313 AxxFxACA 0.407 ARLWDGCG 
Stomach 281 VxPxVNAV 0.512 LTPAVQAV 
Testis 129 RVPRxPxA 0.361 GSPSRPLR 
Thyroid 208 DRDxxFFD 0.330 EYYAGERE 
Yellow Bone Marrow 274 RxAKxAxN 0.295 RLAKVGLN 
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Table 3-16. Summary of motif selection analysis performed using ChemGPS-9D 
amino acid substation matrix and combination score ranking for all patient tissues 
recovered. 
ChemGPS-9D Combo Score 
Tissue Unique Peptides 
Highest 
Scored Motif 
Maximum 
Score 
Example 
Peptide 
Adrenal Gland 168 PFCRAVA 0.043 GVGRCYP 
Aorta 136 VCVVSAV 0.120 VCMLTAV 
Bladder 108 PVxANFVP 0.074 PVWQGRVP 
Bone Marrow 2135 SFVSFA 0.017 TAFSVFS 
Bowel 321 RHRxFxF 0.085 RHRAFLW 
Brain 148 SDRRSSxR 0.083 SDRRTSLR 
Coronary Artery 110 VAHCRAP 0.127 RMAHCRAP 
Duodenum 122 VSFRVAxS 0.073 SSGMRFSV 
Duramater 195 DRDRxAHD 0.093 ERERLGHE 
Esophagus 90 VRNAxxAP 0.078 PGAPAQRL 
Fat 493 SHxFFN 0.118 ISHWFWQ 
Gallbladder 199 VVVxFRDS 0.098 SERYTVLL 
Heart 174 VAxAVNFA 0.183 GFQLGGGL 
Kidney 229 DDxSxRKA 0.072 EEGTLRKG 
Liver 946 VFVxxxAK 0.029 KAGTGVFL 
Liver Tumor 998 RxFxVxNA 0.182 GNQVVFRR 
Lung 82 VxRRxCR 0.139 VYRRSCR 
Lymph Node 1599 RDKVxD 0.021 REKLSEL 
Muscle 912 RSFxNRP 0.114 SRTWVNRP 
Pancreas 91 VAVCAxSA 0.098 ATSGCVGV 
Prostate 344 VSxFVDF 0.231 SWDMFDSI 
Skin 941 PVxRSH 0.067 RHTRILP 
Spleen 655 VxCFDxP 0.102 VCCFETP 
Stomach 106 SHVxxSK 0.094 LKTGTLHS 
Testis 82 SSFDKxR 0.074 MTSWDKYR 
Thyroid 175 RRVVxSN 0.055 ANTVLMRR 
Yellow Bone Marrow 607 RxAKxAxN 0.080 RLAKVGLN 
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Table 3-17. Peptides clustering to top 100 motifs in all 10 analyses. 
Tissue Peptides- All Scores 
Adrenal Gland LRKWNVRW 
Aorta KGATTGHG, KGATTGHV 
Bladder GRYGNSSE 
Bowel EVAAGSSS 
Brain GGSRSLRL 
Duodenum GVIGGITR 
Duramater SAGTADTM, SAGTAGTM 
Esophagus HVGHLKRL, PEHWSAKG, PEHWSAKR, PEHWSAKV 
Fat MWHGTQQR 
Gallbladder DTRETNTG 
Kidney QDRLASAR, QDRLASTR, QDRLASVR 
Liver Tumor SSEGLRAL, TTRKFSDT 
Lymph Node EVSLADRH, EVSLVDRH 
Prostate DSYWAAG, DSYWGAG 
Spleen GTPWTGCG, RLQSTGTN 
Thyroid DRIGSYFD, EYYAGERE, EYYVGERE, RRLVITNV 
Yellow Bone Marrow DALDGFPK, GVNGQKHW, HAWSKSTV, HVWSKSTV 
 
  
 Table 3-18. Peptides clustering to top 100 motifs in all analyses using simple score 
motif ranking. 
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 Table 3-19. Peptides clustering to top 100 motifs in all analyses using combination 
score motif ranking. 
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Table 3-20. Top motifs from liver tumor analysis cross
relevant peptides. PEPBANK database used.
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-referenced with biologically 
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justification for selection is also included. For example, the ligand, amphiregulin, 
contains a region, CQQEYFGERC, that shares sequence similarity with a peptide 
clustered to a top motif in liver tumor. The di-sulfide bonds between the cysteines in this 
region have been shown to be important in interacting with epidermal growth factor 
receptor (EGFR), commonly upregulated on the surface of tumor cells [84, 85]. These 
data suggest that the selected peptide may bind to EGFR and this interaction may imitate 
an endogenous phenomenon specific to tumor cells, leading to further confidence for 
tumor targeting strategies. Furthermore, the sequence CYIQNC/CYFQNC also mimics a 
top motif selected in HCC tissue, and contains a biologically active site found in the 
hormones oxytocin and vasopressin and may also form disulfide bonds important for 
receptor ligation [86]. Using this type of information, additional peptides mimicking the 
binding site for proteins important for biological function can be identified. 
 To determine the significance of our candidate peptides with respect to the 
multidimensional analysis, we examined the sequence homology between SGVGAASL 
and peptides clustering to top 1,000 motifs selected in data recovered from liver tumor 
tissue. Encouragingly, 4 and 5 consecutive amino acid matches were found in each 
analysis (Table 3-21a). Peptides and their respective motifs found to match 5 consecutive 
amino acids to peptide SGVGAASL are shown in Table 3-21b. These data suggest that 
the peptide SGVGAASL is indeed significant in liver tumor tissue as validated by 
multiple selection algorithms. Characterization of this peptide and its corresponding 
receptor warrants further consideration. 
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Table 3-21. Peptide SGVGAASL clustering to top 100 motifs in liver tumor tissue. a) 
Summary of peptides containing four or five amino acid matches to peptide 
SGVGAASL. b) Peptides clustering to top 100 motifs in liver tissue containing five 
amino acid matches to peptide SGVGAASL. Motifs from which the peptides clustered 
are also shown. 
a. 
Amino acid 
substitution 
matrix 
Peptides matching 
4 amino acids 
Peptides matching 
5 amino acids 
BLOSUM62 34 2 
2D 72 8 
ROCS 3 0 
ChemGPS-4D 48 1 
ChemGPS-9D 39 1 
 
b. 
  Amino acid substitution matrix 
  BLOSUM62 2D ChemGPS-4D ChemGPS-9D 
Peptides 
matching 
5 amino 
acids 
SAAGLRAV RHESGLAG WRQSAGGL WRQSAGGL 
SAAGVIWW KGPGVGSR     
  GAAVGMFR     
  KGAALGFR     
  RAGGLAGR     
  RGAGVALR     
  WRQSAGGL     
  QMTLAAGD     
Motifs 
containing 
matching 
peptides 
SxxGLRAL RNDxxxAA FRNSAxA FRNSAxA 
FxLLGAA RxALxAAR     
  FRNSAxA     
  NLxLxAxD     
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3.3  Peptide SGVGAASL mediated targeting of liver tumor cells  
To validate the specificity of the SGVGAASL peptide mediated targeting, peptide 
binding assays were performed to investigate selective phage binding to the surface of 
HCC cells. For HEPG2 cells, phage displaying the SGVGAASL peptide bound to the 
surface of cells ~3 fold more than control insertless phage (p < 0.05, Fig. 3-12a). 
However, for SNU449 cells there was no difference in the number of targeted phage 
binding when compared to insertless phage. These results suggest that the cell surface 
receptor responsible for peptide binding is unique to certain subtypes of HCC. This 
hypothesis was further examined in Chapter 3.5.  
We next performed an internalization assay to determine a functional interaction 
between HCC cells and SGVGAASL-displaying phage. Following 24 hr incubation, 
peptide mediate phage internalization into HEPG2 and SNU449 cells was detected by 
immunofluorescence of permeabilized cells. After incubation with SGVGAASL-
displaying phage, HEPG2 cells internalized phage particles while incubation with 
insertless control phage did not result in internalization of phage (Fig. 3-12b, top panel). 
In accordance with previous experiments, SNU449 cells did not internalize SGVGAASL-
displaying phage or insertless control phage (Fig 3-12b, bottom panel). 
We next performed a pilot in vivo experiment to determine if SGVGAASL can 
mediate peptide targeting in preclinical models of HCC. Orthotopic tumors were grown 
in the liver of mice using HEP3B HCC cells. When tumors reached an appropriate size, 
SGVGAASL peptide labeled with IRDye 800CW Infrared Dye was injected 
intravenously at increasing doses. Images were acquired by a Pearl Impulse Small 
Animal Imaging System (LI-COR) after 72 hr of circulation. Dye signal measured in the  
 a. 
b. 
Fig. 3-12. SGVGAASL-peptide displaying phage binding and internalization in 
HCC cells. a) Phage binding to surface of HCC cells. Relative binding of SGVGAASL
displaying phage to HCC cell lines SNU449 and HEPG2 was assessed by the BRASIL 
assay. Insertless phage was used as negative control. b) Cell internalization of 
SGVGAAS -displaying phage
SGVGAASL-displaying phage for 24 hr (left panels). Insertless phage were used as 
control (right panels). Phage particles (red dots) were detected by labeling with a Cy
conjugated antibody. Cell nuclei were sta
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. HEPG2 and SNU449 cells were incubated with 
ined with DAPI (blue). *p < 0.05. 
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tumor was higher than in the control organ (brain), and the signal increased in a dose 
dependent manner (Fig. 3-13). While these results are preliminary and require more 
extensive study, they are promising towards the development of the SGVGAASL peptide 
for targeted drug delivery or imaging modalities.  
 
3.4 Peptide SGVGAASL endogenous receptor purification  
Peptide affinity was used to isolate proteins binding to SGVGAASL with the goal 
of identifying an endogenous tumor-specific receptor for this peptide. Protein extract was 
incubated with peptide affixed to long arm amine terminated magnetic beads and 
fractionated after washing. Fractionated proteins were incubated with phage displaying 
the SGVGAASL peptide and phage binding was investigated. SGVGAASL–displaying 
phage bound to fractions purified with SGVGAASL peptide incubated with liver tumor 
protein in higher quantities compared to fractions purified from normal liver protein (Fig. 
3-14a), while insertless phage did not bind to either fraction. These data suggest that the 
receptor for the peptide SGVGAASL is either present in higher quantities or in a more 
preferential binding conformation in purified protein from liver tumor than normal liver 
tissue.  
Fractionated proteins were next resolved by 2D gel electrophoresis and compared 
to control fractions (Fig. 3-14b). Unique bands were excised from the gels, digested with 
trypsin and submitted for LC-MS/MS based protein analysis. Mass spectrometric peptide 
mapping analysis revealed signatures that matched the protein giantin, a 376kDa golgi 
membrane protein that has no previously described function in cancer. 
  
  
 
 
 
Fig. 3-13. SGVGAASL peptide homing to orthotopic HCC tumors in mice.
were intravenously injected with 10
labeled with IRDye 800CW infrared dye. Signal in tumor and brain tissue was measured 
after 72 hr of circulation time using a Pearl Impulse Small Animal Imaging System (LI
COR) 
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 µg, 15 µg, 30 µg, or 50 µg of SGVGAASL peptide 
 
 Animals 
-
 a. 
b. 
Fig. 3-14. Receptor purification for SGVGAASL peptide.
eluted by peptide affinity chromatography to phage displaying the peptide SGVGAASL. 
In the eluted fraction, a positive protein
compared to binding with insertless phage. b) 2
performed on proteins purified by peptide affinity chromatography. Two protein sources 
were used for the purification: no
(right). Proteins from normal tissue were purified by peptide affinity chromatography as a 
control (left panel). Proteins purified from liver tumor tissue are shown in the right panel. 
Circled bands were exclusively present in fractions purified from liver tumor tissue. 
These bands were excised and sent to mass spec for identification. 
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 a) Binding of proteins 
-peptide interaction was measured when 
-dimensional gel electrophoresis was 
rmal human tissue (left) and human liver tumor tissue 
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To confirm the binding interaction between giantin and the SGVGAASL peptide, 
we performed binding assays using SGVGAASL- displaying phage with proteins 
immunoprecipitated from liver tumor protein extract with an anti-giantin antibody. This 
allowed for isolation of the receptor in a structural confirmation that is most 
representative to that found in liver tumor. Furthermore, recombinant giantin was not 
commercially available and immunocapture techniques represented the best option to 
isolate it. Phage displaying the SGVGAASL peptide were incubated with 
immunocaptured giantin and bound phage were quantified using real-time PCR (Fig. 3-
15). As expected, targeted phage bound to immunocaptured giantin in higher quantities 
compared to insertless phage. Neither phage bound to a control coating of BSA. These 
data suggest that phage displaying the SGVGAASL peptide bind to giantin in vitro. 
 
3.5 Giantin expression in patient tissue 
After validating the interaction between the peptide SGVGAASL and giantin, we 
next examined the expression of this protein in patient samples. Previously, giantin has 
been described as a Golgi membrane protein in the literature and expression has not been 
linked to cancer. Here, we found a distinct expression pattern in liver tumor samples 
obtained from patient 6 (Fig. 3-16). Expression of giantin was significantly upregulated 
in tumor tissue compared to normal liver with significant vascular localization. IHC 
giantin staining showed moderate to strong membranous staining in the endothelium, 
however, staining in malignant cells was negative. This finding was unexpected given 
that in vitro studies using HCC cell lines have shown that giantin is present on the tumor  
  
  
Fig. 3-15. SGVGAASL-peptide displaying phage binding to immunocaptured 
receptors. Antibodies against giantin as well as BSA were used to immunocapture 
proteins extracted from human liver tumor tissue. SGVGAASL
incubated with immunocaptured proteins and following washing, were quantified using 
real-time PCR. Insertless phage was used as a negative control and showed binding at 
background levels. **p < 0.01.
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 Fig. 3-16. Giantin staining in HCC and normal liver tissue sections obtained from 
patient 6. 
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cell membrane and SGVGAASL peptide binds to the surface of HCC cells (Chapter 
3.6).  
Due to the unique expression pattern for giantin observed in a subset of HCC 
samples, we next explored the expression of this protein in a large cohort of HCC patient 
samples including whole slide tissue sections of patient HCC tissue as well as a HCC 
TMA comprised of 142 samples. A similar study was designed to evaluate expression of 
giantin in several normal tissues including liver, prostate, testis, heart, and placenta and 
other cancers including prostate, breast, colon, non-small cell lung, and ovarian cancer to 
provide a comprehensive evaluation of giantin as a molecular marker of HCC and 
potentially other cancers. 
 
3.5.1 Giantin expression in HCC patient samples 
We expanded our tissue study to include slides from 30 patients with HCC 
provided by a collaborator, Dr. Steven Curley (Department of Surgical Oncology, 
University of M.D. Anderson Cancer Center, present address: Department of Surgery, 
Baylor College of Medicine). Of the 30 patient samples, 12 samples (40%) exhibited a 
similar vascular membrane expression pattern of giantin as observed in patient 6 (Fig. 3-
17). Of the remaining samples, 14/30 or 47% exhibited increased cytoplasmic expression 
of giantin, and 4/30 or 13% of samples exhibited very low overall giantin expression. 
These data suggest that the vascular expression pattern may not be restricted to patient 6, 
but may be observed in a unique subset of patients with HCC. This observation was 
further confirmed in a small cohort of HCC samples obtained commercially (N=7). Each 
HCC tumor sample was provided with a sample of adjacent healthy liver tissue. When  
 Fig. 3-17. Giantin staining in archival tissue specimens
Immunohistochemistry was performed on tissue sections using an anti
Vascular staining was observed in 12/30 (40%) of samples (top row). Cytoplasmic 
staining was observed in 14/30 (47%) samples (middle row). Negative staining for 
giantin was observed in 4/30 (13%) samples (bottom row).
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 from HCC patients.
-giantin antibody. 
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giantin localization was examined, we observed a unique vascular cell surface expression 
pattern in a subset of HCC patients (4 out of 7 samples, 57%) while adjacent normal 
tissue showed no vascular membranous staining (Fig. 3-18).  
Next, three full tissue specimens each including HCC tumor tissue, adjacent 
benign tissue, and vessels were examined. Malignant cells in HCC showed only weak, 
limited nuclear and cytoplasmic staining (Fig. 3-19a). Positive staining was observed in 
the endothelium lining the capillaries (sinusoids) within both tumor and benign liver 
parenchyma. Staining was localized to the basal membranes and sometimes to the 
extracellular space adjacent to malignant cells and again appeared to be associated with 
vasculature (Fig. 3-19a). In our previous studies, endothelial cells demonstrated 
particularly intense staining in HCC compared to in normal liver tissue. However, in the 
samples used in this study, there was no association of the intensity or prevalence of 
endothelial staining in malignant areas compared to surrounding benign tissues (Fig. 3-
19a). Of note, positive giantin expression in the vasculature of benign tissue may be 
affected by the associated disease processes in the benign liver tissue adjacent to tumors. 
Specifically, two of the samples displayed cirrhosis in benign liver tissue, the major risk 
factor for HCC, and the third showed fatty changes (steatosis) (Fig. 3-19b).  
 
3.5.2 Giantin expression in a HCC tissue microarray 
Large scale analysis of giantin expression in patient tissue was performed by 
analysis of a HCC TMA. The TMA composed of liver tumor (N=131), normal liver 
(N=4), and inflammatory liver (N=6) patient samples was acquired from BioChain and 
stained for giantin expression. Staining intensity was recorded on a scale of 0-4  
  
 
 
 
 
Fig. 3-18. Giantin protein expression in HCC tissue specimens and adjacent normal 
liver tissue. Immunohistochemistry was performed on commercially obtained HCC 
samples and adjacent normal
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 liver tissue using an anti-giantin antibody. 
 
 
 Fig. 3-19. Giantin staining in human HCC cancer and benign liver tissue.
Immunohistochemistry was performed using an anti
in malignant cells and vessels (left) and hep
staining in additional tissue types including liver parenchyma and cirrhotic liver.
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-giantin antibody. a) Giantin staining 
atocytes and vessels (right). b) Giantin 
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(0=negative, 1=minimal, 2=faint, 3=moderate, 4=strong). Of the 131 liver tumor samples, 
86 (65%) exhibited minimal to strong staining of giantin in the tumor vasculature. Of the 
six inflammatory liver tissues, all (100%) exhibited minimal to faint staining of giantin in 
the vasculature. Of the four normal liver samples, two (50%) exhibited minimal to faint 
staining of giantin in the vasculature. Carry-over controls of full tissue liver samples 
(patient 6 HCC tissue sample and benign liver tissue sample) showed staining that was 
similar to previous studies, in which the malignant sample showed positive staining in 
vasculature that was not apparent in the normal sample. 
Analysis of TMA staining results determined that there was an overall higher 
expression of giantin in the tumor vasculature when compared to normal samples (Fig. 3-
20b). 20% of HCC samples (N=23) exhibited moderate to strong staining in the 
endothelium compared to only faint to negative staining in normal endothelium (N=4). 
There was no difference in giantin expression in malignant cells in HCC samples when 
examined by tumor grade (Fig. 3-21a); however, when examined by tumor stage, 
malignant cells in HCC exhibited higher expression of giantin in more advanced stage 
tumors (T4) when compared to all other stages (T1-T3) (Fig. 3-21c). In HCC-associated 
vasculature, giantin expression was moderate to strong in high and low grade (I, I-II, and 
III) tumors but lower in middle grade tumors (II and II-III) (Fig. 3-21b). This correlation 
was also observed in HCC associated vasculature when examined by tumor stage. Stage 
T1 and T4 tumors exhibited higher vascular expression of giantin compared to stage T2 
and T3 tumors (Fig. 3-21d). In both malignant cells and vascular cells, there was no 
correlation between giantin expression and patient age (Fig. 3-21e-f).  
  
 Fig. 3-20. Giantin staining in normal and diseased human liver tissue.
giantin staining in malignant cells (cholangiocarcinoma and HCC), or normal hepatocytes 
(normal and inflammatory tissue). b) Scores for giantin staining in vascular cells found in 
diseased and normal liver tissue.
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 a) Scores for 
 
 Fig. 3-21. Giantin staining in HCC tissue by patient and tumor characteristics.
Scores for giantin staining in malignant cells (a), or vascular cells (b) by tumor grade. 
Scores for giantin staining in malignant cells (c), or vascu
Scores for giantin staining in malignant cells (e), or vascular cells (f) by patient age.
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lar cells (d) by tumor stage. 
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Given the diversity and semi-qualitative nature of histological metrics coupled 
with the complications of biomarker scarcity associated with TMAs, inferences about 
statistical significance are not necessarily evident especially when scored a single time 
[87, 88]. However, when a subpopulation of samples defined by positive (nonzero) 
vascular giantin expression were examined, there was an increase in staining in HCC 
samples when compared to inflammatory tissue as well as normal liver tissue that was 
determined to be statistically significant by chi-squared testing (p < 0.05, Fig. 3-22a). 
Likewise, when HCC samples with positive expression of giantin in malignant cells were 
examined, vascular staining was increased in positive malignant cells. Stronger malignant 
cell staining correlated with stronger endothelial cell staining (Fig. 3-22b). 
For samples of inflammatory liver (N=6), there was no difference in giantin 
antibody staining compared to normal hepatocytes and malignant tissue (Fig. 3-20a). 
However, there was an increase in vascular staining for giantin in endothelial cells 
associated with inflammatory liver tissue compared to endothelial cells associated with 
normal liver (Fig. 3-20b). 
Several samples of cholangiocarcinoma (N=14, bile duct carcinoma) were 
included, and appeared to show more intense and consistent staining in malignant cells 
than the HCC samples (Fig. 3-20a); however, vascular staining of giantin in 
cholangiocarcinoma did not differ from vascular staining in HCC samples (Fig. 3-20b). A 
single sample (N=1) of metastatic HCC colon adenocarcinoma exhibited moderate to 
strong malignant cell staining (score=3.5) as well as faint vascular cell staining (score=2). 
For the TMA, all of the cases were in duplicate, and the staining was very consistent 
between cores from the same samples. 
 Fig. 3-22. Giantin staining in HCC vasculature.
endothelial cells in HCC, inflammatory, and normal liver tissue. b) Scores for giantin 
staining in endothelial cells by malignant cell score.
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  a) Scores for giantin staining in 
 *p < 0.05, Χ2 test. 
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3.5.3 Giantin expression in normal patient tissue 
Giantin staining was examined in a panel of normal tissues to establish baseline 
expression. In a sample of normal liver obtained from a 60-year-old female, giantin 
antibody showed faint membranous staining in sinusoidal endothelium and minimal 
staining in hepatocytes. Strong staining was present in intravascular leukocytes and 
minimal staining was occasionally present in bile ducts and vascular smooth muscle (Fig. 
3-23a). In a sample of normal prostate obtained at surgery from a 49-year-old male, 
giantin antibody showed faint to moderate staining in glandular epithelium while stroma 
was negative (Fig. 3-23b). In a sample of normal testis obtained at surgery from a 37-
year-old male, giantin antibody showed moderate to strong cytoplasmic, nuclear, and 
membranous staining in seminiferous precursors, and minimal cytoplasmic and nuclear 
staining in Leydig cells (Fig. 3-23c). In a sample of normal heart obtained at autopsy 
from a 24-year-old female, giantin antibody showed faint staining in endothelium, but 
cardiomyocytes were negative (Fig. 3-23d). In a sample of normal placenta obtained at 
surgery from a 25-year-old female, giantin expression was absent (Fig. 3-23e). 
 
3.5.4 Giantin expression in additional cancers 
 Giantin expression was also examined in five additional tumor types including 
prostate, breast, colon, non-small cell lung, and ovarian cancer. Whole slide specimens 
containing tumor tissue, benign tissue, and vessels were examined. Prostate carcinomas 
showed the most prominent expression of giantin, with intense cytoplasmic staining in 
malignant cells that was stronger than staining in surrounding benign prostate epithelium 
(Fig. 3-24a-c). In one sample, staining was more prominent in higher grade malignant  
  
 
 
 
Fig. 3-23. Giantin staining in normal human tissue.
performed on tissues from a) liver, b) prostate, c) testis, d) heart, and e) placenta using an 
anti-giantin antibody. 
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  Immunohistochemistry was 
 
 
 Fig. 3-24. Giantin staining in human prostate 
Immunohistochemistry was performed using an anti
in malignant glands (top left), normal glands (top right), tumor vessel (bottom left), and 
normal vessel (bottom right). b) Giantin s
benign hyperplastic glands, and normal glands. c) Giantin staining in malignant glands, 
intraepithelial neoplasia, and normal glands.
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cancer and normal prostate tissue.
-giantin antibody. a) Giantin staining 
taining in grade 4 and grade 3 prostate cancer, 
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tissue, compared to lower grade tumor and benign hyperplastic glands (Fig. 3-24b). 
Another sample showed intense staining in prostatic intraepithelial neoplasia, similar to 
the associated invasive tumor and significantly stronger than staining in benign glands 
(Fig. 3-24c). Endothelium exhibited moderate membranous and extracellular staining in 
larger vessels, but showed only minimal to faint staining in capillaries. There was no 
relationship to intensity of staining in endothelium when compared to proximity to tumor 
(Fig. 3-24a). 
In breast cancers, malignant cells displayed frequent intense cytoplasmic staining 
as well as weaker membranous staining (Fig. 3-25a). Staining in the malignant cells was 
more uniform and generally stronger than staining in benign ducts and lobules (Fig. 3-
25a). One sample showed more prominent staining in the myoepithelial cell layer of 
benign ducts and lobules compared to the inner glandular layer lining glandular lumen 
(Fig. 3-25a top), whereas a second sample showed the opposite pattern and was negative 
in myoepithelial cells but positive in the luminal glandular epithelium (Fig. 3-25a 
bottom). Vascular staining was not observed in breast cancer or adjacent benign tissue 
(Fig. 3-25b). 
Colon cancers showed positive staining that was similar to the staining observed 
in benign glandular epithelium in two samples (Fig. 3-26a), and variable in a third, with 
areas of intense staining and large areas that were completely negative (Fig. 3-26b). 
There was only minimal staining in vasculature and no differential staining with respect 
to proximity of tumor versus benign tissue (Fig. 3-26c). 
NSCLC exhibited positive staining that was similar to staining in benign 
respiratory epithelium but stronger than staining in benign pneumocytes in two of three  
  
Fig. 3-25. Giantin staining in human breast cancer and normal
Immunohistochemistry was performed using an anti
in malignant cells (left) and normal cells (right). b) Giantin staining in tumor vessels 
(left) and normal capillaries (right).
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 breast tissue.
-giantin antibody. a) Giantin staining 
 
 
  
 Fig. 3-26. Giantin staining in human colon cancer and normal colon tissue.  
Immunohistochemistry was performed using an anti
in malignant glands (left) and normal mucosa (right) for two patients. b) Giantin staining 
in malignant glands (left) and normal
expression in tumor vessels (left) and normal
112 
 
-giantin antibody. a) Giantin staining 
 mucosa (right) for an additional patient. c) Giantin 
 vessels (right). 
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samples (Fig. 3-27a). The third sample showed strong staining in malignant cells, but 
only minimal staining in benign respiratory epithelium (Fig. 3-27b top). In this sample, 
there was also an increased association of staining in tumor vessels compared to benign 
vessels (Fig. 3-27b bottom). Only minimal staining was present in vasculature for the 
remaining samples (example shown in Fig. 3-27c). Additional cell types in lung that 
showed positive staining included benign alveolar macrophages, reactive type II 
pneumocytes, and neutrophils (Fig. 3-27d). 
Ovarian carcinomas displayed relatively prominent staining in malignant cells, 
with mostly cytoplasmic staining (Fig. 3-28a). Only minimal staining was present in 
vasculature and there was no particular association with vascular staining in the ovarian 
carcinomas (Fig. 3-28b). 
Based on these results, giantin expression appeared to vary not only by cancer 
type but in some cases, by patient. While higher overall expression was observed in 
several cancer types when compared to adjacent normal tissue, vascular expression of 
giantin was found to be unique to a subset of HCC patients indicating that peptide 
mediated targeting would be most beneficial in this setting. 
 
3.6  Giantin cell surface expression in HCC and endothelial cells 
We next examined the expression of giantin on the surface of HCC cells. Protein 
from each cell line was fractionated and giantin expression was measured in the plasma 
membrane fraction by Western blot analysis. In HEP3B cells, giantin expression was 
found in the plasma membrane fraction whereas control proteins MEK1/2 (cytoplasm) 
and Golgi 58K (Golgi complex) were not, thus confirming successful fractionation  
 Fig. 3-27. Giantin staining in human non
and normal lung tissue.  Immunohistochemistry was performed using an anti
antibody. a) Giantin staining in malignant cells (left) and normal
b) In an additional patient, differential giantin staining in malignant cells (top left) and 
normal airway cells (top right) as well as tumor vessels (bottom left) and normal vessels 
(bottom right). c) Giantin expression in tumor vessels (left) and normal
a patient with NSCLC. d) Giantin expression in additional cell types inclu
macrophages, reactive type II pneumocytes and neutrophils.
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 Fig. 3-28. Giantin staining in human ovarian cancer and normal ovarian tissue.
Immunohistochemistry was performed using an anti
in malignant cells for three patients. b) Giantin staining in tumor vessels (left) and normal 
vessels (right). 
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enrichment (Fig. 3-29a). In SNU449 cells, giantin membrane expression was found to be 
lower than with HEP3B cells.  
The plasma membrane fraction isolated from HEP3B cells was used to examine 
phage binding. Giantin was immunocaptured from plasma membrane fractions and 
incubated with phage (displaying the SGVGAASL peptide or no peptide as a negative 
control). Bound phage were quantified by ELISA using an HRP-labeled anti-phage 
antibody. For the plasma membrane fraction, SGVGAASL- peptide displaying phage 
bound to proteins captured by the giantin antibody but not to proteins captured by 
MEK1/2 (intracellular marker) or BSA (Fig. 3-29b). These results confirm that giantin 
was present in the plasma membrane fraction and that the binding event between phage 
displaying the peptide SGVGAASL and giantin is not dependent on subcellular 
localization.  
Cell surface localization of giantin was confirmed by FACS analysis on live cells. 
HCC cell lines, HEP3B, HEPG2, and SNU449 were each examined. As controls, 
expression of intracellular proteins MEK1/2, Golgi membrane protein 58K, and nuclear 
protein Orc2 were also examined. For live cells, giantin was detectable on the surface of 
HEP3B and HEPG2 cells but not on SNU449 cells while intracellular, Golgi, and nuclear 
markers were each negative (Fig. 3-30a). When the cell membrane was permeabilized 
and intracellular proteins were included in the analysis, each marker was positive and 
giantin staining increased as expected. Furthermore, when giantin expression was 
examined in HDMECs, cell surface expression was also slightly positive, supporting the 
vascular staining pattern observed in histology (Fig. 3-30b). Interestingly, when 
HDMECs were activated with VEGF which is known to stimulate endothelial cell  
  
a. 
b. 
Fig. 3-29. SGVGAASL displaying phage binding to giantin purified from plasma 
membrane protein fraction of HCC cells.
total protein extract as well as plasma membrane proteins isolated from the HEP3B and 
SNU449 cell lines. Expression of giantin as well as intracellular proteins MEK1/2 and 
58K were examined. b) Giantin and MEK1/2 
incubated with plasma membrane protein fraction isolated from the HEP3B cell line. 
Wells were coated with BSA as a negative control. Immunocaptured proteins were 
incubated with SGVGAASL displaying phage or insertless p
detected using an HRP conjugated anti
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 a) Western blot analysis was performed on 
antibodies were isolated in wells and 
hage overnight, washed, and 
-phage antibody. **p < 0.01. 
 
 Fig. 3-30. Cell surface expression of giantin on HCC cells and endothelial cells.
FACS analysis was performed on live and permeabilized HCC cell lines HEP3
HEPG2, and SNU449 using an antibody against giantin (bottom panels). As controls, 
FACS analysis using antibodies against a cytoplasmic protein (MEK1/2), a nuclear 
protein (Orc2), and a Golgi organelle protein (58K) was also performed. Results for 
control experiments are shown in HEP3B cells (top panels) but were similar in all cell 
lines. b) FACS analysis was performed on live and permeabilized HDMEC endothelial 
cells using an antibody against giantin. Prior to FACS analysis, cells were starved in 
media not containing growth factors or FBS for 24 hr then activated with VEGF for 4 hr.
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proliferation, migration, sprouting, and permeability, the expression of giantin on the 
surface increased. These results coupled with histological studies and Western blot 
analysis on fractionated proteins confirm in a live cell setting that giantin is expressed on 
the cell surface of HCC cell lines and endothelial cells. 
 
3.7 Giantin function in HCC cells 
In order to examine the function of giantin in cancer cells, we constructed shRNA 
lentivirus targeting giantin mRNA. HEP3B cells were infected with targeted virus and, 
after 48 hr, expression of giantin protein was eliminated (Fig. 3-31a). Interestingly, the 
cleaved caspase-3 marker for apoptosis was not positive in any cells indicating that 
giantin silencing does not lead to apoptosis. The proliferation marker, Ki67, was not 
positive in giantin depleted cells, but positive in cells infected with untargeted virus or 
non-infected cells. The adhesion marker, E-cadherin, was decreased in giantin 
knockdown cells, suggesting a role for giantin in cell adhesion and proliferation 
mechanisms. Furthermore, 72 hr after viral infection, cell morphology was examined. In 
giantin depleted cells, cell morphology drastically changed when compared to non-
infected cells and cells infected with untargeted constructs (Fig. 3-31b). Loss of adhesion 
and a decrease in proliferation were again observed. Furthermore, when giantin depleted 
HEP3B cells were grown on a plate that measures changes in electric potential in real 
time (Roche xCELLigence), an overall lag in cell attachment after 8 hr and decrease in 
proliferation after 48 hr when compared to untreated cells were observed (Fig. 3-32a,b).   
  
  
 
 
 
Fig. 3-31. Giantin knockdown in HEP3B cells.
cells. Cells were incubated with shRNA targeting giantin mRNA or control non
virus for 24 hr, media was refreshed with media containing puromycin antibiotic (5 
µg/mL). Cells were harvested 24 hr after selecti
blot analysis. b. Phenotypic analysis of giantin knockdown in HEP3B cells. Cells were 
incubated with shRNA targeting giantin mRNA or control non
media was refreshed with media containing pu
images of cells were taken 24 hr after selection.
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on and protein was extracted for Western 
-targeted virus for 24 hr, 
romycin antibiotic (5 µg/mL). Light field 
 
 
 
-targeted 
                            a. 
                            b. 
Fig. 3-32. Cell adhesion and proliferation kinetics following shRNA
depletion of giantin in HEP3B cells.
mRNA for 24 hr, media was refreshed with media containing puromycin antibiotic (5 
µg/mL). Cells were harvested 48 hr after selection and plated 
Plates (Roche) at 104 cells per well. The Roche xCELLigence machine which measures 
electrical impedance in real time as cells attached and grow on E
to take measurements every minute for 48 hrs where a) represents data recorded from 0
hr and b) represents all data recorded.
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CHAPTER 4: DISCUSSION 
 
The high-throughput, bacteria-free phage display approach described in this work 
involves the implementation of next-generation sequencing to facilitate synchronous 
selection in multiple human tissues in a single screening round. This methodology allows 
for screenings to be performed 1,000 x faster and 250 x cheaper while recovering an 
increase of 2 to 4 orders of magnitude in the number of sequences. Approximately 1.5 
million peptides sequences were recovered from a phage display screen in a patient with 
primary HCC and RCC utilizing the Roche 454 sequencing platform. Normal as well as 
diseased tissues were examined to build a comprehensive overview of molecular 
heterogeneity in the human vasculature. 
In order to analyze these large datasets, we developed a relational database with 
the ability to extract amino acid sequences from raw DNA sequencing data recovered 
from phage isolated in each tissue, query for peptide sequences and calculate saturation 
of recovered data in each tissue. This tool has been designed to be accessible online as a 
valuable academic resource for groups studying vascular markers present in both normal 
and disease physiology. Likewise, we have developed an advanced bioinformatic 
workflow to select for significant peptide motifs in tissues of interest. By considering the 
multidimensional characteristics associated with short peptides including amino acid 
sequence, physiochemical properties, shape/pharmacophoric properties, and “druglike” 
properties, panels of tissue-specific motifs were identified in 27 human tissues, including 
HCC. Many peptides identified through these analyses overlapped, further increasing our 
confidence in their specificity to target organs.  
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Furthermore, peptides selected from HCC tissues were cross-referenced with the 
PepBank database (a compilation of biologically relevant peptide sequences made 
publically available online). A preliminary analysis uncovered 14 endogenous ligands 
involved in cancer that matched to top peptides we identified in HCC. Addition of this 
validation step in the bioinformatics workflow would allow for more informed 
hypotheses of potential receptor/ligand complexes uncovered in phage display screens as 
well as aid in the selection of peptide ligands that have functional roles in disease 
development and progression.  
Each selectively identified peptide represents a potential targeting ligand for 
delivery of drugs or imaging agents in humans. As future studies, it would be interesting 
to examine these data sets in the context of ligand heterogeneity between human and non-
human primates. Recently, a colony of rhesus macaques was found to carry germline 
mutations that cause the equivalent of the human genetic disease, Lynch syndrome, also 
known as Hereditary Non-Polyposis Colon Cancer (HNPCC) where mutations in the 
DNA mismatch repair pathway leads to an increased risk of cancer. A phage display 
screen was performed in a rhesus with HNPCC and recovered phage DNA was processed 
as described for the human patient and sequenced using the Illumina HiSeq platform. 
Sequence analysis of 25 different tissues recovered over 101 million peptide sequences. 
Since this initial animal, we have performed screens in three additional rhesus macaques 
with colon adenocarcinoma arising from HNPCC. We plan to compile and cross-
reference this extensive database of almost half a billion peptide sequences recovered 
from phage display screens in humans, non-human primates, pigs, mice, and rats. 
Identification of the same tissue specific motifs in multiple species will reinforce their 
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specificity, adding great value and confidence for drug-delivery strategies. Likewise, 
knowledge of divergent motifs in specific tissues would be of significant value as these 
would represent poor candidates for testing in preclinical models. 
As the next step in bioinformatics analysis, we plan to continue to develop and 
improve our ability to study large-scale datasets. For example, topological data analysis 
involves the use of algorithms to uncover qualitative geometric insights from complex 
data [89]. For high-throughput phage display applications, these insights would include 
defining the multi-dimensional shape and connectedness of clusters containing ligands in 
an organ or tissue of interest. A similar analysis has previously been performed using 
high-throughput microarray data collected in a cohort of breast cancer patients. By 
computationally identifying shape characteristics in the high-dimensional data previously 
only defined by tumor or normal samples, investigators were able to distinguish between 
several molecular subtypes of disease and define a previously unknown subgroup with 
excellent survival [90]. We plan to develop methods to compute the fundamental 
geometric properties of our dataset and next apply statistical tools in order to extract 
subgroups of clusters that represent novel targeting moieties for tissues of interest. This 
complex analysis would allow for the identification of even more robust molecular 
targets in disease as well as serve to further our understanding of the vascular map. 
Although we have generated an extensive list of organ and tissue specific motifs 
and peptides, here, we chose to focus on HCC and introduce a novel tumor targeting 
peptide. In cancer therapy, the molecular heterogeneity of the vascular endothelium is an 
important determinant for the selective homing of drugs to diseased tissue. The use of 
combinatorial phage library selection has previously been highly successful towards 
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translational applications to treat or image disease in humans. These strategies are 
especially advantageous in diseases with an angiogenic component including HCC 
tumors. Identification of vascular markers directly in humans enables confidence in the 
translation of targeted delivery strategies to the clinic. Cell surface binding assays as well 
as in vitro internalization assays both showed that phage displaying the SGVGAASL 
peptide bound and internalized into the HCC cell line, HEPG2, while untargeted control 
phage did not. A pilot in vivo experiment in mice bearing orthotopically implanted HCC 
tumors showed that SGVGAASL peptide labeled with infrared dye localized to the tumor 
site in a dose-dependent manner. These data suggest that peptide SGVGAASL could 
potentially be used as a novel probe for the targeting of HCC vascular beds.  
Targeting of drugs and imaging agents to both diseased and normal tissues are of 
high interest for a plethora of therapeutic strategies including delivery of cytotoxic and 
imaging agents as well as gene therapy vectors. We plan to proceed with the conjugation 
of SGVGAASL to the pro-apoptotic moiety D[KLAKLAK]2 as a selective therapy in 
HCC. Extensive biodistribution, pharmacokinetic, and survival studies will be performed 
in preclinical models of HCC established using cell lines both positive (HEP3B and 
HEPG2) and negative (SNU449) for SGVGAASL peptide binding and receptor 
expression.  
Recently, targeted therapy has been explored in the context of tumor 
heterogeneity. It is well known that within a cancer type, there exists multiple cell sub-
populations arising from a Darwinian clonal evolution driven by genetic instability and 
harboring distinct phenotypic alterations [91, 92]. Molecular therapy strategies aiming to 
interfere with these specific aberrant mechanisms driving cancer growth and progression 
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are challenged by high failure rates due to a lack of systemic specificity or limited 
efficacy in only a small number of patients [92]. Predictive biomarkers that aid in the 
assignment of targeted therapy in patients who are identified by their molecular profile as 
able to benefit represent the next step towards improving their clinical care. In fact, the 
FDA has already implemented a “one-arm adaptive trial” for fast tracking the clinical 
development of drugs for which a predictive biomarker is already defined as a companion 
diagnostic [92].  
Here, the purification of the corresponding receptor that serves as the tumor-
specific target for SGVGAASL peptide-mediated binding allows for the concurrent 
identification of a biomarker that could potentially predict patient response to a drug 
targeted by the SGVGAASL peptide. Selective binding of phage displaying the 
SGVGAASL peptide to the giantin protein was confirmed using immunocapture binding 
assays where nontargeted phage showed very low binding. When the experiment was 
repeated using giantin isolated from plasma membrane fractions, phage displaying the 
SGVGAASL peptide still bound preferentially to immunocaptured giantin suggesting 
that the conformation of the interaction site is not altered based on the cellular 
localization of giantin. Preliminary IHC analysis on patient HCC tissue uncovered a 
subset of patients that exhibited high expression of giantin on the surface of tumor-
associated endothelial cells. We predict that this subgroup of patients would benefit the 
most from a therapy targeted through giantin ligand/receptor interaction. Potentially 
moving forward with clinical studies, giantin expression could be used to stratify patients 
into those predicted to respond to SGVGAASL targeted therapy, supporting the 
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qualification for fast track status and greatly reducing the time and costs associated with 
clinical trials. 
Previously, giantin has been described as a conserved Golgi membrane protein 
that may participate in the formation of intercisternal cross-bridges of the Golgi complex 
[93]. Structurally, giantin has a single transmembrane domain at the C-terminus that 
anchors the protein to the Golgi membrane. The remaining 350 kDa domain is located in 
the cytoplasm and forms a rod shaped structure made up of coiled-coiled (heptad) repeats 
(estimated to be 1.5 x 250 nm in total size). Giantin behaves similarly to a secretory 
protein where, after translation, it inserts into the endoplasmic reticular (ER) membrane, 
is incorporated into transport vesicles and retained in the Golgi [94]. The cytoplasmic 
domain forms a highly elongated disulfide linked homodimer that serves as the receptor 
for the p115 protein and facilitates docking of COPI vesicles (transport cargo from ER to 
Golgi and back) to the Golgi membrane [95-97]. 
 In an extensive study of giantin expression in human tissue, strong staining in the 
tumor endothelium was observed in a subset of HCC patient samples. Out of 30 samples 
obtained from the Surgical Oncology Department at the University of Texas MD 
Anderson Cancer Center, 40% exhibited similar endothelial cell surface expression as 
observed in patient 6. Commercially obtained HCC samples paired with adjacent normal 
liver tissue (N=7) also confirmed this vessel expression pattern as well as an overall 
increase in giantin expression in tumor tissue where normal liver tissue showed no 
vascular expression.  When a TMA containing 142 samples of liver tumor, inflammatory 
liver, and normal liver patient tissue was evaluated, giantin expression was positive on 
the membrane of tumor vasculature in over 65% of HCC tissues. Early and late stage 
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tumors exhibited higher vascular expression of giantin and malignant cell expression of 
giantin correlated with higher vascular expression of giantin. When samples positive for 
giantin in the vasculature were examined, HCC samples exhibited the strongest staining 
when compared to inflammatory liver samples and normal liver samples which never 
exhibited more than faint staining in the vasculature. Again, these results confirm in a 
large sample size that expression of giantin in the vasculature is increased on the surface 
of endothelial cells within the tumor microenvironment. This unique membrane 
expression represents an excellent target for tumor specific delivery of imaging and drug 
agents. 
In a study of five additional cancer types (prostate, breast, colon, lung, and 
ovarian cancer), giantin was expressed in higher quantities in malignant tissue from the 
prostate, breast, and ovarian malignant tissue compared to benign tissue. However, 
significant vascular expression of giantin was not observed in any of the five cancer types 
studied. This may be because hepatic sinusoids also referred to as open pore capillaries 
are composed of specialized fenestrated endothelium that sometimes has different 
staining characteristics compared to endothelium in other tissues [98]. The specialized 
nature of the hepatic vessels may explain differences in giantin expression in the small 
vessels associated with hepatic malignancies as compared to other types of cancers. 
Flow cytometry experiments showed that giantin, the endogenous receptor 
mediating SGVGAASL binding, is expressed on the surface of HCC cell lines HEPG2 
and HEP3B but not on the surface of SNU449 cells. These findings were confirmed by 
examination of giantin expression on plasma membrane protein fractions in these cell 
lines. These results correlate with previous findings showing that SGVGAASL peptide 
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displaying phage exhibited no preferential specificity to the HCC cell line, SNU449. 
These findings are in contrast to immunohistochemical analysis in patient tissues where 
giantin expression was not positive on the membrane of malignant cells; however, this 
discrepancy may be due to the presence of mosaic tumor vessels in HCC. In fact, 
characterization of tumor vasculature in an orthotopic mouse model of HCC established 
using the HEP3B cell line revealed that over 60% of vessels present were mosaic (contain 
both tumor and endothelial cells making up the luminal surface of the endothelium) [99]. 
Cell surface expression of giantin was also observed in activated HDMEC 
endothelial cells; however, overall expression was quite low compared to HCC cell lines. 
It is known that endothelial cell heterogeneity varies significantly between organ systems 
and is not easily modeled in in vitro settings [4, 100]. Furthermore, our studies have 
shown that the increased expression of giantin on the plasma membrane is only 
significantly observed in vessels associated with HCC. Thus, it is unlikely that significant 
plasma membrane expression of giantin would be observed in endothelial cells derived 
from human skin. 
Interestingly, the subcellular localization of giantin has never been described with 
respect to the plasma membrane. However, in the literature, there are multiple cases of 
proteins exhibiting dual functionality in multiple cellular compartments. An example 
from our own group involves work performed by Mintz et al. in 2009 where it was found 
that the intracellular protein Crkl is released from tumor cells and binds to β1 integrins on 
the cell surface, going on to trigger downstream signaling events [101]. Conditional 
localization on the cell surface has been identified for multiple types of intracellular 
molecules including proteins involved with stress-response and nuclear proteins 
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including transcription factors and DNA repair proteins where translocation usually 
occurs in response to environmental stress [23, 25, 102-105]. Functionality on the cell 
surface may be distinct from intracellular functions and some have been shown to 
promote metastasis and invasion in cancer and represent ideal targets for anti-cancer 
therapy [23, 101, 106]. For example, the heat-shock protein GRP78 is part of an 
evolutionarily conserved, ER-linked stress response mechanism that provides cellular 
survival signals during environmental and physiologic duress including acidosis, hypoxia 
and imbalanced glucose metabolism occurring in tumor cells [107, 108]. We, and others, 
have previously demonstrated that GRP78 can exist on the surface of breast cancer cells 
and that the abundance of cell-surface localized GRP78 increases during metastatic 
progression [25, 109, 110]. Fusion of a pro-apoptotic motif to a GRP78 targeting peptide 
enabled the induction of cell death in breast cancer metastatic nodules establishing the 
usefulness of conditional cell surface proteins for the targeted delivery of cytotoxic drugs 
[111]. 
Aberrant giantin function has also never been linked to involvement in any type 
of cancer. However, an examination of normal giantin function uncovered a role for 
Golgi dysfunction in several human diseases. Previous work has shown that increased 
and dispersed giantin expression occurs during vascular remodeling in both primate 
models of pulmonary artery hypertension (PAH) as well as in patients with PAH [112, 
113]. A hallmark of PAH is persistent hypoxia where Golgi fragmentation occurs as a 
result of the cellular response to stress. In hypoxic pulmonary arterial endothelial cells, 
Golgi tether impairment was observed as well as cytoplasmic dispersal and increased 
cellular content of the giantin protein leading to a promotion in cell mitosis and 
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proliferation [112-114]. Hypoxia is known to promote invasion, metastasis, and drug 
resistance in HCC as well as several other types of solid tumors [115-117]. In the future, 
we plan to examine the link between increased overall giantin expression during hypoxia 
and stress in the context of tumor establishment, progression, and aggressiveness as well 
as translocation of giantin to the surface of tumor-associated endothelial cells.  
In our studies, shRNA-mediated depletion of giantin in HCC cells led to a 
decrease in cell proliferation indicating that giantin function is required for cell survival. 
This does not come as a surprise given the pivotal role of giantin in Golgi apparatus 
function and cellular trafficking; however, when giantin expression was silenced in HCC 
cells, we also found that cells exhibited a loss of adhesion. Cell adhesion dysfunction is a 
critical component during cancer invasion and metastasis [118]. Previous work involving 
siRNA-mediated depletion of giantin has been performed in the HeLa cell line where 
knockdown of giantin expression resulted in alterations in glycosylation of cell surface 
proteins [119]. Interestingly, in this study, no changes in cell proliferation or adhesion 
were observed suggesting a unique role for giantin in HCC. 
In addition to links to hypoxia and giantin function, antibodies against giantin 
have been found in the circulation of patients with autoimmune disorders including lupus 
erythematosus and Sjögren's syndrome as well as those positive for human 
immunodeficiency virus [120, 121]. Furthermore, anti-giantin positive sera exhibit low 
titer for antibodies recognizing epitopes in the C-terminal transmembrane domain of 
giantin and high titer with strong reactivity for antibodies recognizing the N-terminal and 
central domains that are located on the cytoplasmic extension of giantin anchored in the 
Golgi membrane [120]. Further analysis of the SGVGAASL peptide binding site will 
132 
 
focus on localizing the binding affinity to the C- or N-terminal domain of giantin. Most 
likely, we will observe similar binding affinities as circulating autoantibodies against 
giantin indicating a similar mechanism for exposure of the protein to the extracellular 
environment through its transmembrane domain.  
During apoptosis, giantin rapidly undergoes site specific caspase-3 mediated 
cleavage at a conserved site shutting down vesicular trafficking between the ER and 
Golgi apparatus [122]. One group hypothesizes that when cells undergo unregulated cell 
death including apoptosis or necrosis resulting from injury, infection, or failure to clear 
dying cells, the giantin protein may be recognized as a cell surface structure [120]. 
Combined with the findings of giantin function in hypoxic and apoptotic cells, a 
tantalizing role for this protein in inflammation arises. In many cancers, inflammation 
plays an important role in cancer growth and progression [123]. In particular, the 
hallmark risk factor for HCC is cirrhosis and chronic liver disease which involves each of 
the disease states described above: inflammation, cell death and hypoxia collectively 
resulting in promotion of angiogenesis and tumor initiation [124]. We have shown that 
faint expression of giantin in the vasculature was observed in all samples of inflammatory 
liver including viral hepatitis related cirrhosis and fatty liver (steatosis).  In the future, we 
plan to examine giantin expression and cellular localization in a premalignant setting 
perhaps identifying a role for giantin as a marker for HCC risk.  
An additional translational path of study we will focus on involves the integration 
of the SGVGAASL peptide into a multi-functional hybrid vector incorporating adeno-
associated virus (AAV) genomic elements and M13-derived phage [125]. This ligand-
targeted, AAV/phage (AAVP) chimera displaying a tumor specific peptide will mediate 
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selective internalization of the viral particles through specific ligand-receptor interactions 
as well as facilitate the delivery of reporter genes that can be used for imaging, diagnosis 
and treatment of disease. If a link to giantin expression and premalignancy is uncovered, 
this type of delivery strategy would serve as an excellent modality for disease detection 
and identifying patients at risk of developing HCC. Furthermore, towards developing a 
therapy against HCC, this platform also allows for reporter gene control at the 
transcriptional level through insertion of promoters active in cells of interest. Although 
our giantin binding peptide may bind at different levels to both inflammatory liver 
vasculature as well as tumor vasculature, integration of a tumor specific promoter or 
inflammatory liver specific promoter to drive transgene expression would allow for 
selective expression of the transgene only in cells of interest. Moving forward, we have 
plans to thoroughly explore the activity of HCC targeted AAVP constructs in multiple 
models of liver disease and liver tumors so as to realize its clinical potential. 
In conclusion, the examination of high-throughput data sets recovered from phage 
screenings directly in a patient offers a plethora of opportunities for uncovering novel 
protein interactions in the vasculature of normal and disease tissue. Many of these 
interactions can be exploited for drug delivery or imaging purposes as well as examined 
for roles in disease persistence and progression. As our understanding of the vascular 
landscape expands, functional discovery of complex protein networks involved in normal 
and disease functions combined with accumulating genomic knowledge has the potential 
to make a significant impact in our understanding of disease mechanisms as well as 
innovations in clinical care.  
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